<SEC-DOCUMENT>0001213900-25-103109.txt : 20251028
<SEC-HEADER>0001213900-25-103109.hdr.sgml : 20251028
<ACCEPTANCE-DATETIME>20251028162613
ACCESSION NUMBER:		0001213900-25-103109
CONFORMED SUBMISSION TYPE:	F-3
PUBLIC DOCUMENT COUNT:		19
FILED AS OF DATE:		20251028
DATE AS OF CHANGE:		20251028

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-291122
		FILM NUMBER:		251425176

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-3
<SEQUENCE>1
<FILENAME>ea0262630-f3_neurosense.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
filed with the Securities and Exchange Commission on October 28, 2025.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
F-3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroSense
Therapeutics Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable<BR>
(Translation of Registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State
    of Israel</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
    Applicable</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction
    of <BR>
    Incorporation or Organization)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary Standard Industrial
    <BR>
    Classification Code Number)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.&nbsp;Employer <BR>
    Identification Number)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11
HaMenofim Street, Building B<BR>
Herzliya 4672562 Israel<BR>
+972-9-7996183</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
Including Zip Code, and Telephone Number, Including Area Code, of Registrant&rsquo;s Principal Executive Offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cogency
Global Inc.<BR>
122 East 42<SUP>nd</SUP> Street,<BR>
18<SUP>th</SUP> Floor, New&nbsp;York, NY&nbsp;10168<BR>
(212)&nbsp;947-7200<BR>
</B>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Copies&nbsp;to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; padding-bottom: 2.25pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Robert
    L. Grossman, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gary
    Emmanuel, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
    Huberman, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Greenberg
    Traurig, P.A.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>One
    Azrieli Center</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Round
    Tower, 30th Floor</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>132
    Menachem Begin Rd</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel
    Aviv, Israel 6701101</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>+1
    212 801 9337</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Perry&nbsp;Wildes
    <BR>
    Goldfarb Gross <BR>
    Seligman&nbsp;&amp; Co. <BR>
    One&nbsp;Azrieli&nbsp;Center <BR>
    Tel&nbsp;Aviv&nbsp;6702100,&nbsp;Israel <BR>
    +972&nbsp;(3)&nbsp;607-4444</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public: </B>As soon as practicable after the effective date of this Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check
the following box.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under
the Securities Act&nbsp;of&nbsp;1933, check the following box.&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act&nbsp;of&nbsp;1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S.&nbsp;GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards<SUP>&dagger;
</SUP>provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term &ldquo;new or
    revised financial accounting standard&rdquo; refers to any update issued by the Financial Accounting Standards Board to its Accounting
    Standards Codification after April&nbsp;5, 2012.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section&nbsp;8(a)&nbsp;of the Securities Act&nbsp;of&nbsp;1933, as amended, or until the Registration Statement shall
become effective on such date as the Commission, acting pursuant to such Section&nbsp;8(a), may determine.</B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>SUBJECT
    TO COMPLETION DATED OCTOBER 28, 2025</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>333,334
Ordinary Shares </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the resale, from time to time, by the selling shareholder identified in this prospectus under the section &ldquo;Selling
Shareholder,&rdquo; (the &ldquo;selling shareholder&rdquo;) of NeuroSense Therapeutics Ltd. (&ldquo;NeuroSense,&rdquo; &ldquo;we,&rdquo;
&ldquo;us&rdquo; or the &ldquo;Company&rdquo;) of 333,334 of our ordinary shares, no par value per share (the &ldquo;Shares&rdquo;) issued
to the selling shareholder under a securities purchase agreement, dated September 4, 2025 (the &ldquo;Purchase Agreement&rdquo;), by
and between us and the purchaser named therein. The Shares were offered pursuant to the exemptions provided in Section&nbsp;4(a)(2) under
the Securities Act&nbsp;of&nbsp;1933, as amended (the &ldquo;Securities Act&rdquo;), and Regulation&nbsp;D promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling shareholder will receive all of the proceeds from any sales of the resale of Shares offered hereby. We will not receive any of
the proceeds, but we will incur expenses in connection with such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling shareholder may sell the Shares covered by this prospectus through public or private transactions at market prices prevailing
at the time of sale, at negotiated prices or such other prices as such selling shareholder may determine. The timing and amount of any
sale are within the sole discretion of such selling shareholder. Our registration of the Shares for resale covered by this prospectus
does not mean that the selling shareholder will offer or sell any of the Shares. For further information regarding the possible methods
by which the Shares may be distributed, see &ldquo;Plan of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; and a &ldquo;foreign private issuer&rdquo;, each as defined under federal securities laws,
and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings.
See &ldquo;Prospectus Summary&nbsp;&mdash;&nbsp;Implications of Being an Emerging Growth Company&rdquo; and &ldquo;Prospectus Summary&nbsp;&mdash;&nbsp;Implications
of Being a Foreign Private Issuer&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares and warrants to purchase our ordinary shares are listed on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the
symbols &ldquo;NRSN&rdquo; and &ldquo;NRSNW.&rdquo; On October 27, 2025, the closing price for our ordinary shares was $1.14 and the
closing price for the warrants to purchase our ordinary shares was $0.3592.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities is highly speculative and involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 8 to read
about factors you should consider before buying the Shares.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the
accuracy or adequacy of the disclosures in this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">TRADEMARKS, SERVICE MARKS AND TRADENAMES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">MARKET AND INDUSTRY DATA</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">THE OFFERING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">THE PRIVATE PLACEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">MARKET FOR ORDINARY SHARES AND DIVIDEND POLICY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">SELLING SHAREHOLDER</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">DESCRIPTION OF OUR SECURITIES BEING REGISTERED</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015">EXPENSES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_017">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_018">ENFORCEMENT OF CIVIL LIABILITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_019">WHERE CAN YOU FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_020">INCORPORATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of the registration statement on Form&nbsp;F-3 that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
for the offering of the Shares by the selling shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not assume that the information contained in, or incorporated by reference into, this prospectus is accurate on any date subsequent
to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or the Shares covered by this prospectus
are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in, or incorporated
by reference into, this prospectus in making your investment decision. You should also read and consider the information in the documents
to which we have referred you under the caption &ldquo;Where You Can Find Additional Information&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the selling shareholder have authorized anyone to provide any information or to make any representation other than those contained
in, or incorporated by reference into, this prospectus. You must not rely upon any information or representation not contained in, or
incorporated by reference into, this prospectus. This prospectus does not constitute an offer to sell or the solicitation of an offer
to buy any of our securities other than the securities covered hereby, nor does this prospectus constitute an offer to sell or the solicitation
of an offer to buy any of our securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation
in such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, including the information incorporated by reference herein, contains forward-looking statements that are subject to a number
of risks and uncertainties, many of which are beyond our control. See &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Note&nbsp;Regarding
Forward-Looking Statements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>TRADEMARKS,
SERVICE MARKS AND TRADENAMES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NeuroSense Therapeutics logo and other trademarks and service marks of NeuroSense Therapeutics Ltd. appearing in this prospectus or the
information incorporated by reference herein are the property of the Company. Solely for convenience, some of the trademarks, service
marks, logos and trade names referred to in this prospectus are presented without the&nbsp;<SUP>&reg;</SUP>&nbsp;and&nbsp;<SUP>&trade;</SUP>&nbsp;symbols,
but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our
rights to these trademarks, service marks and trade names. This prospectus, including the information incorporated by reference herein,
contains additional trademarks, service marks and trade names of others. All trademarks, service marks and trade names appearing in this
prospectus or the information incorporated by reference herein are, to our knowledge, the property of their respective owners. We do
not intend our use or display of other companies&rsquo; trademarks, service marks, copyrights or trade names to imply a relationship
with, or endorsement or sponsorship of us by, any other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>MARKET
AND INDUSTRY DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, including the information incorporated by reference herein, contains industry, market and competitive position data that
are based on industry publications and studies conducted by third parties as well as our own internal estimates and research. These industry
publications and third-party&nbsp;studies generally state that the information that they contain has been obtained from sources believed
to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that each of these
publications and third-party&nbsp;studies is reliable, we have not independently verified the market and industry data obtained from
these third-party&nbsp;sources. Forecasts and other forward-looking&nbsp;information obtained from these sources are subject to the same
qualifications and uncertainties as the other forward-looking&nbsp;statements included in, or incorporated by reference into, this prospectus.
While we believe our internal research is reliable and the definition of our market and industry are appropriate, neither such research
nor these definitions have been verified by any independent source.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus and certain information incorporated by reference herein contain forward-looking&nbsp;statements within the meaning of Section&nbsp;27A
of the Securities Act and Section&nbsp;21E of the U.S.&nbsp;Securities Exchange&nbsp;Act&nbsp;of&nbsp;1934, as amended (the &ldquo;Exchange&nbsp;Act&rdquo;),
and other securities laws. Many of the forward-looking&nbsp;statements contained in, or incorporated by reference into, this prospectus
can be identified by the use of forward-looking&nbsp;words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;would&rdquo; and other similar expressions that are predictions of or indicate future
events and future trends, although not all forward-looking&nbsp;statements contain these identifying words.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking&nbsp;statements
are based on our management&rsquo;s beliefs and assumptions and on information currently available to our management. Such statements
are subject to substantial risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking&nbsp;statements
due to a variety of factors, including, but not limited to, those identified under the section titled &ldquo;Risk Factors&rdquo; in this
prospectus or the documents incorporated herein. These risks and uncertainties include factors relating to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain the listing of our ordinary
    shares on Nasdaq;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the going concern reference in our financial statements
    and our need for substantial additional financing to achieve our goals;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our limited operating history
    and history of incurring significant losses and negative cash flows since our inception, which we anticipate will continue for the
    foreseeable future;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our dependence on the success
    of our lead product candidate, PrimeC, including our obtaining of regulatory approval to market PrimeC in the United States (&ldquo;U.S.&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our limited experience
    in conducting clinical trials and reliance on clinical research organizations and others to conduct them;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to advance
    our preclinical product candidates into clinical development and through regulatory approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of our clinical
    trials, which may fail to adequately demonstrate the safety and efficacy of our product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to achieve
    the broad degree of physician adoption and use and market acceptance necessary for commercial success;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reliance on third parties
    in marketing, producing or distributing products and research materials for certain raw materials, compounds and components necessary
    to produce PrimeC for clinical trials and to support commercial scale production of PrimeC, if approved;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our receipt of regulatory
    clarity and approvals for our therapeutic candidates and the timing of other regulatory filings and approvals;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates of our expenses,
    revenues, capital requirements and our needs for additional financing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our efforts to obtain,
    protect or enforce our patents and other intellectual property rights related to our product candidates and technologies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of the public
    health, political and security situation in Israel, the U.S. and other countries in which we may obtain approvals for our products
    or our business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impacts on our ongoing
    and planned trials and manufacturing as a result of the war in Israel; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">those factors referred
    to in our most recent Annual Report on Form 20-F incorporated by reference herein in &ldquo;Item 3. Key Information &mdash; D. Risk
    Factors,&rdquo; &ldquo;Item 4. Information on the Company,&rdquo; and &ldquo;Item 5. Operating and Financial Review and Prospects,&rdquo;
    as well as in our most recent Annual Report on Form 20-F generally, which is incorporated by reference into this prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preceding list is not intended to be an exhaustive list of all of our risks and uncertainties. As a result of these factors, we cannot
assure you that the forward-looking&nbsp;statements in this prospectus or the documents incorporated herein or therein will prove to
be accurate. Furthermore, if our forward-looking&nbsp;statements prove to be inaccurate, the inaccuracy may be material. In light of
the significant uncertainties in these forward-looking&nbsp;statements, you should not regard these statements as a representation or
warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that &ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus or any document incorporated herein or therein,
and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and
our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to
release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of
unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus, the documents incorporated herein and therein, completely and with the understanding that our actual future
results may be materially different from what we expect. We qualify all of our forward-looking&nbsp;statements by these cautionary statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights information contained elsewhere in or incorporated by reference into this prospectus that we consider important. This
summary does not contain all of the information you should consider before investing in our securities. Before you decide to invest in
our securities, you should read the entire prospectus carefully, including the &ldquo;Risk Factors&rdquo; section and the financial statements
and related notes incorporated by reference into this prospectus and the other documents incorporated by reference into this prospectus,
which are described under &ldquo;Incorporation by Reference&rdquo; before making an investment in our securities.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biotechnology company focused on discovering and developing treatments for people living with neurodegenerative
diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer&rsquo;s disease (AD) and Parkinson&rsquo;s disease (PD). We believe
these diseases represent some of the most significant unmet medical needs of our time, with limited effective therapeutic options available.
The burden of these diseases on both patients and society is substantial. For example, the average annual cost of ALS alone is $180,000
per patient, and its estimated annual burden on the U.S.&nbsp;healthcare system is greater than $1&nbsp;billion. Due to the complexity
of neurodegenerative diseases, our strategy is utilizing a combined therapeutic approach to target multiple disease-related pathways.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead therapeutic candidate, PrimeC, is a novel extended-release oral formulation, fixed-dose combination of two FDA-approved drugs, ciprofloxacin
and celecoxib. PrimeC is designed to treat ALS by modulating microRNA synthesis, iron accumulation, and neuroinflammation, all of which
are hallmarks of ALS pathology. The U.S. Food and Drug Administration, or the FDA and the European Medicines Agency, or the EMA have
granted PrimeC orphan drug designation for the treatment of ALS. In addition, the EMA has granted PrimeC the Small and Medium-Sized Enterprise,
or SME, status, which offers significant potential benefits leading up to and following drug regulatory approval. We believe PrimeC&rsquo;s
multifunctional mechanism of action has the potential to significantly prolong lifespan and improve ALS patients&rsquo; quality of life,
thereby reducing the burden of this debilitating disease on both patients and healthcare systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PrimeC
was evaluated in PARADIGM, a Phase&nbsp;2b randomized, multi-center, multinational, prospective, double-blind, placebo-controlled study,
to evaluate safety, tolerability, and efficacy of PrimeC in 68 people living with ALS.&nbsp;Participants were being administered PrimeC
or placebo at a 2:1 ratio, respectively, for the six-month double-blind part. Study participants were allowed to continue standard of
care treatment of approved products. The primary endpoints of the study are an evaluation of ALS-biomarkers as well as safety and tolerability
assessment. Secondary and exploratory endpoints are the evaluation of clinical efficacy (ALS Functional Rating Scale&nbsp;&mdash;&nbsp;Revised,
or ALSFRS-R, and slow vital capacity), survival, and improvement in quality of life. All subjects who completed the six-month double-blind,
placebo-controlled dosing period had the opportunity to be transferred to the PrimeC active arm for a 12-month open label extension.
The study completed enrollment in May&nbsp;2023, enrolling 69 participants, in which 68 are living with ALS and one participant who was
misdiagnosed for ALS and was excluded from the evaluations. Four ALS clinical centers participated in the study in three territories:
Israel, Italy, and Canada. In December 2023, we reported that we met the primary safety and tolerability endpoints and achieved secondary
clinical efficacy endpoints in the top-line results of our 6-month double-blind phase of PARADIGM. In May 2024, we announced new positive
data analysis from PARADIGM clinical trial demonstrating statistically significant slowing of disease progression in high-risk ALS patients.
In July 2024, we announced results from the 12-month analysis of the PARADIGM clinical trial which showed a significant improvement in
the rate of decline of ALS Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for subjects who received PrimeC from
the start of the trial compared to those who started on placebo. In August 2024, we announced positive 12-month biomarker data from the
PARADIGM clinical trial, which showed a significant decrease in ferritin levels and a corresponding increase in transferrin levels, both
indicating alleviation of the pathology. In October 2024, we completed the full 18-month dosing in PARADIGM, and in December 2024, we
announced results from the 18-month analysis of the PARADIGM clinical trial which showed statistically significant positive results from
the 18-month data analysis of the PARADIGM study, evaluating the efficacy of PrimeC in the treatment of ALS. In February 2025, we announced
additional findings from an 18-month analysis of the PARADIGM clinical trial showing improvements in two additional endpoints, complication-free
survival (analysis which includes death from any cause or respiratory insufficiency&nbsp;or hospitalization due to ALS-related complications)
and Slow Vital Capacity (SVC), measuring respiratory function. In September 2025, we announced a new analysis of 18-month data of the
PARADIGM clinical confirming that the observed benefit of initiating PrimeC early in disease progression is consistent after accounting
for patient variability. Such results highlighted the potential of PrimeC to meaningfully extend survival in ALS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the FDA&rsquo;s recommendation for additional non-clinical data to support long term use of Ciprofloxacin (as PrimeC is intended for
long-term administration in treating ALS) a long-term tox study was initiated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2024, we announced the successful completion of the in-life phase of the study, as we move towards the initiation of a Phase
3 study in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, we concluded a productive Type C meeting with the FDA. The purpose of the meeting was to discuss the design of a proposed
Phase 3 clinical study and the plan for submission of an eventual 505(b)(2) marketing application. In light of the FDA&rsquo;s feedback,
we plan to submit a final protocol to the FDA during the first half of 2025 and approach the EMA, with the aim of commencing enrollment
of the pivotal Phase 3 study in the second half of 2025, which would include approximately 300 patients divided by a ratio of 2:1, PrimeC
to placebo. The Phase 3 study is expected to be a randomized, multi-center, multinational, prospective, double-blind, placebo-controlled
study, with an open label extension (OLE), to evaluate the efficacy and safety of PrimeC in people living with ALS. Following 12 months
of treatment, it is expected that all participants will transition to PrimeC for a 12-month open label extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, we entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization
of PrimeC, in certain key territories. The closing of this transaction is subject to finalization of a definitive agreement and there
can be no assurance as to the timing of, or whether, such an agreement will ultimately be executed, and if executed, what would be the
final terms of such an agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PrimeC
was previously evaluated in a Phase&nbsp;2a clinical trial, or NST002, in 15 people living with ALS, conducted at the Tel Aviv Sourasky
Medical Center, Israel. The primary endpoint of the NST002 trial, which was safety and tolerability, was met. In this trial, the safety
profile observed was consistent with known safety profiles of ciprofloxacin and celecoxib. Side effects were mild and transient in nature.
There were no new or unexpected safety signals detected during the trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we observed positive clinical signals in comparison to virtual controls, and a serum biomarker analysis showed significant changes following
treatment, indicating biological activity of the drug in comparison to untreated matched ALS patients. All 12 patients who completed
the NST002 trial elected to continue into an extension study with PrimeC, that was conducted as an Investigator Initiated Study. To date,
we are still supporting the drug supply for a few of the participants in this study, which is over than 40&nbsp;months since NST002 was
initiated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed three additional studies in 2022 as part of our drug development program to further support our future regulatory submissions.
In April&nbsp;2022, we initiated a pharmacokinetic, or PK, study, or NCT05232461, of PrimeC.&nbsp;The PK open-label, randomized, single-dose,
three-treatment, three-period crossover study evaluated the effect of food on the bioavailability of PrimeC as compared to the bioavailability
of co-administered ciprofloxacin tablets and celecoxib capsules in adult subjects in the U.S.&nbsp;under an FDA cleared IND protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August&nbsp;2022, we completed enrollment and dosing of all subjects in a multi-dose PK study, or NCT05436678. On September&nbsp;28,
2022, we released the results of the NCT05436678 study. Based on results, we believe the PK profile of PrimeC supports the formulation&rsquo;s
extended-release properties, as the concentrations of the active components have been synchronized, aiming to potentially maximize the
synergism between the two compounds. In June&nbsp;2022, we reported the successful completion of the &ldquo;in-life&rdquo; phase of its
90-day GLP toxicology study. In this study, the components of PrimeC, celecoxib and ciprofloxacin, were administered to rodents at doses
4x the maximal clinical dose. All animals appeared normal, with no significant findings observed. We intend to present the data from
these studies to the FDA as part of PrimeC&rsquo;s drug development plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we have a strong patent estate, including patents on method of use, combination, and formulation. We have secured U.S. Patent
10,980,780 relating to methods for treatment of ALS using ciprofloxacin and celecoxib, the components of PrimeC, which expires in 2038.
Equivalent patents also have been issued in the European Patent Office, Canada, Australia, Israel and Japan. The patent estate also includes
US Patent 12,097,185, which relates to Prime C formulations. This patent will expire in December 2042. Equivalent applications are pending
in many jurisdictions worldwide. We also expect to take advantage of orphan drug exclusivity for PrimeC, if approved, for seven years
in the United States and ten years in the European Union. In addition, U.S. patent application 16/623,467, which relates to methods of
treatment of neurodegenerative disease using combinations of ciprofloxacin and celecoxib, is currently pending. This patent application,
once granted, is expected to expire on June 20, 2038.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
organization is built around a management team with extensive experience in the pharmaceutical industry, with a particular focus on ALS
research and clinical trials. We believe that our leadership team is well-positioned to lead us through clinical development, regulatory
approval and commercialization of our product candidates. Furthermore, we maintain steadfast and extensive communication and collaboration
with patient advocacy groups and associations, underscoring the importance of patient perspectives in advancing therapeutic strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to PrimeC, we extended our pipeline and conducted research and development efforts for AD and PD, with a similar strategy of
combined products. The following chart represents our current product development pipeline:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Standby
Equity Purchase Agreement with YA</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 31, 2024, we entered into the Standby Equity Purchase Agreement (&ldquo;Standby Equity Purchase Agreement&rdquo;) with YA II
PN, LTD., a Cayman Islands exempt limited partnership (&ldquo;YA&rdquo;). Pursuant to the Standby Equity Purchase Agreement, the Company
has the right, but not the obligation, to sell to YA from time to time (each such occurrence, an &ldquo;Advance&rdquo;) up to $30.0 million
(the &ldquo;Commitment Amount&rdquo;) of our ordinary shares during the 36 months following the execution of the&nbsp;Purchase Agreement,
subject to the restrictions and satisfaction of the conditions in the Standby Equity Purchase Agreement. At our option, the ordinary
shares would be purchased by YA from time to time at a price equal to 97% of the lowest of the three daily VWAPs during a three consecutive
trading day period commencing on the date that we, subject to certain limitations, deliver a notice to YA that the Company is committing
Yorkville to purchase such ordinary shares (the &ldquo;Advance Shares&rdquo;).&nbsp;We may also specify a certain minimum acceptable
price per share in each Advance.&nbsp;&ldquo;VWAP&rdquo; means, for any trading day, the daily volume weighted average price of our ordinary
shares for such trading day on the Nasdaq Stock Market during regular trading hours as reported by Bloomberg L.P. As consideration for
YA&rsquo;s irrevocable commitment to purchase our ordinary shares up to the Commitment Amount, we issued 224,697 ordinary shares (the
&ldquo;Commitment Shares&rdquo;) to YA and also paid a $25,000 structuring fee to YA. As of the date of this prospectus, we have sold
175,000 Advance Shares to YA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Standby Equity Purchase Agreement, YA shall not be obligated to purchase or acquire any ordinary shares under the Standby Equity
Purchase Agreement which, when aggregated with all other ordinary shares beneficially owned by YA and its affiliates, would result in
the beneficial ownership of YA and its affiliates (on an aggregated basis) to exceed 4.99% of the then outstanding voting power or number
of our ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>December
2024 Private Placement</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2024, we entered into a Securities Purchase Agreement with Rimon&nbsp;Gold&nbsp;Assets,&nbsp;Ltd. and Alon Ben-Noon, the
Company&rsquo;s Chief Executive Officer, pursuant to which we agreed to issue and sell, in a private placement (the &ldquo;December 2024
Private Placement&rdquo;) by us directly to the purchasers (i) 2,343,729 ordinary shares; (ii) Warrants exercisable for an aggregate
of 8,000,000&nbsp;ordinary shares at an exercise price of $1.25 per share (the &ldquo;December 2024 Ordinary Warrants&rdquo;); and (iii)
Pre-Funded Warrants exercisable for an aggregate of 1,656,271 ordinary shares at an exercise price of $0.0001 per share (the &ldquo;December
2024 Pre-Funded Warrants&rdquo;). The purchase price of each ordinary share and accompanying two warrants was $1.25, and the purchase
price of each December 2024 Pre-Funded Warrant and accompanying December 2024 Ordinary Warrant was $1.2499. The gross proceeds from the
December 2024 Private Placement were $5.0 million, before deducting offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
December 2024 Ordinary Warrants are exercisable immediately upon issuance at an exercise price of $1.25 per share and expire five years
from the date of issuance. The December 2024 Pre-Funded Warrants are exercisable immediately upon issuance at an exercise price of $0.0001
per share and may be exercised at any time until the December 2024 Pre-Funded Warrants are exercised in full. As of the date of this
prospectus, 1,380,000 December 2024 Pre-Funded Warrants have been exercised. A holder of December 2024 Ordinary Warrants or December
2024 Pre-Funded Warrants (together with its affiliates) may not exercise any portion of such warrants to the extent that the holder would
own more than 9.99% of our outstanding ordinary shares immediately after exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>September
2025 Private Placement</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 4, 2025, we entered into the Purchase Agreement with the selling shareholder, pursuant to which we agreed to issue and sell,
in a private placement by us directly to the purchaser, 333,334 ordinary shares (the &ldquo;September 2025 Private Placement&rdquo;).
The purchase price of each Share was $1.50. The gross proceeds from the September 2025 Private Placement were approximately $0.5 million,
before deducting offering expenses payable by us of approximately $28,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, on September 9, 2025 we issued to the purchaser the subscribed for Shares against payment of
$0.5 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, we are registering for resale on this registration statement on Form F-3, 333,334 Shares issued
to the selling shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
legal and commercial name is NeuroSense Therapeutics Ltd. We were incorporated on February&nbsp;13, 2017 and were registered as a private
company limited by shares under the laws of the State of Israel. We completed our initial public offering on the Nasdaq in December&nbsp;2021.
Our ordinary shares and warrants to purchase our ordinary shares are traded on the Nasdaq under the symbol &ldquo;NRSN&rdquo; and &ldquo;NRSNW,&rdquo;
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 11 HaMenofim Street, Building B, Herzliya, 4672562 Israel, and our telephone number is +972-9-7996183.
Our website address is&nbsp;<I>www.neurosense-tx.com</I>. The information on our website does not constitute a part of this prospectus.
Our agent for service of process in the United&nbsp;States is Cogency Global Inc., 122 East 42<SUP>nd</SUP>&nbsp;Street, 18<SUP>th</SUP>&nbsp;Floor,
New&nbsp;York, NY&nbsp;10168.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company with less than $1.235&nbsp;billion in revenue during our last fiscal year, we are an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act&nbsp;of&nbsp;2012 (the &ldquo;JOBS Act&rdquo;). As such, we may take advantage
of certain exemptions from various reporting requirements that are applicable to other publicly traded entities that are not emerging
growth companies. These exemptions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to have
    our registered independent public accounting firm attest to management&rsquo;s assessment of our internal control over financial
    reporting;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to comply
    with any requirement that may be adopted by the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;), regarding mandatory
    audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial
    statements (i.e., an auditor discussion and analysis);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to submit
    certain executive compensation matters to stockholder advisory votes, such as &ldquo;say-on-pay,&rdquo; &ldquo;say-on-frequency&rdquo;
    and &ldquo;say-on-golden&nbsp;parachutes&rdquo;;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the audit reports of our
    independent registered public accounting firm do not require communication of critical audit matters; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to disclose
    certain executive compensation related items such as the correlation between executive compensation and performance and comparisons
    of the chief executive officer&rsquo;s compensation to median employee compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, the information contained in this prospectus and the documents incorporated by reference herein may be different from the information
you receive from other public companies in which you hold shares. We may take advantage of these provisions for up until we are no longer
an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of: (i)&nbsp;the last&nbsp;day
of the first fiscal year in which our annual gross revenues exceed $1.235&nbsp;billion; (ii)&nbsp;the date on which we have issued more
than $1&nbsp;billion in non-convertible&nbsp;debt securities during the previous three&nbsp;years; (iii)&nbsp;the date on which we are
deemed to be a &ldquo;large accelerated filer&rdquo; as defined in Rule&nbsp;12b-2&nbsp;under the Exchange&nbsp;Act; or (iv)&nbsp;the
last&nbsp;day of the fiscal year following the fifth anniversary of our initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being a Foreign Private Issuer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a non-U.S.&nbsp;company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as
long as we continue to qualify as a foreign private issuer under the Exchange&nbsp;Act, we will be exempt from certain provisions of
the Exchange&nbsp;Act that are applicable to U.S.&nbsp;domestic public companies, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sections of the Exchange
    Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sections of the Exchange
    Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit
    from trades made in a short period of time; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rules under the Exchange
    Act requiring the filing with the SEC of quarterly reports on Form 10-Q&nbsp;containing unaudited financial statements and other
    specified information, and current reports on Form&nbsp;8-K&nbsp;upon the occurrence of specified significant events.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
these exemptions, we will file with the SEC, within four&nbsp;months after the end of each fiscal year, or such applicable time as required
by the SEC, an Annual Report on Form&nbsp;20-F&nbsp;containing financial statements audited by an independent registered public accounting
firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private
issuer at such time as more than 50% of our outstanding voting securities are held by U.S.&nbsp;residents and any of the following three
circumstances applies: (i)&nbsp;the majority of our executive officers or directors are U.S.&nbsp;citizens or residents; (ii)&nbsp;more
than 50% of our assets are located in the U.S.; or (iii)&nbsp;our business is administered principally in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
foreign private issuers and emerging growth companies also are exempt from certain more stringent executive compensation disclosure rules.
Thus, even if we no longer qualify as an emerging growth company, but remain a foreign private issuer, we will continue to be exempt
from the more stringent compensation disclosures required of companies that are neither an emerging growth company nor a foreign private
issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities&nbsp;offered&nbsp;by&nbsp;the
    selling shareholder for resale</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333,334 Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
    shares as of October 27, 2025</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,550,970
ordinary shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the Shares offered
    by the selling shareholder for resale pursuant to this prospectus will be sold by the selling shareholder. We will not receive any
    proceeds from such sales. See the section titled &ldquo;Use of Proceeds&rdquo; in this prospectus for more information. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offering
    price</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Shares offered by the
    selling shareholder under this prospectus may be offered and sold at prevailing market prices, negotiated prices or such other prices
    as the selling shareholder may determine. See the section titled &ldquo;Plan of Distribution&rdquo; in this prospectus for more information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See the section titled
    &ldquo;Risk Factors&rdquo; beginning on page 8 and the other information included in this prospectus for a discussion of factors
    you should consider before deciding to invest in the Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ordinary shares and
    warrants to purchase ordinary shares are listed on The Nasdaq Capital Market under the symbols &ldquo;NRSN&rdquo; and &ldquo;NRSNW,
    respectively.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise stated, all information in this prospectus, is based on 29,550,970 ordinary shares outstanding as of October 27, 2025, and
does not include the following as of that date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,084,128
    ordinary shares issuable upon the exercise of options outstanding, at a weighted average exercise price of $2.31 per share under our
    2018 Share Option Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000
ordinary shares issuable upon the vesting of restricted share units, or RSUs, outstanding under our 2018 Share Incentive Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,970,406
ordinary shares reserved for issuance and available for future grant under our 2018 Share Incentive Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,535,000
ordinary shares underlying warrants with a weighted average exercise price of $1.83 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">276,271 ordinary shares
    underlying pre-funded warrants; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Advance Shares and any additional shares we may
    issue to YA pursuant to the Standby Equity Purchase Agreement should we elect to sell such shares to YA.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should carefully consider the risks described below and the risks described in our 2024 Annual Report, which are incorporated by reference
herein, as well as the financial or other information included in this prospectus or incorporated by reference in this prospectus, including
our consolidated financial statements and the related notes, before you decide to buy our securities. The risks and uncertainties described
below are not the only risks facing us. We may face additional risks and uncertainties not currently known to us or that we currently
deem to be immaterial. Any of the risks described below, and any such additional risks, could materially adversely affect our business,
financial condition or results of operations. In such case, you may lose all or part of your original investment. The discussion of risks
includes or refers to forward-looking statements; you should read the explanation of the qualifications and limitations on such forward-looking
statements discussed elsewhere in this prospectus supplement under the caption &ldquo;Cautionary Statement Regarding Forward-Looking
Statements&rdquo; above.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
sale of a substantial amount of our ordinary shares, including resale of the shares held by the selling shareholder in the public market
could adversely affect the prevailing market price of our ordinary shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of substantial amounts of our ordinary shares or warrants in the public market, or the perception that such sales might occur, could
adversely affect the market price of our ordinary shares, and the market value of our other securities. We cannot predict if and when
the selling shareholder may sell such shares in the public markets. Furthermore, in the future, we may issue additional ordinary shares
or warrants or other equity or debt securities convertible into ordinary shares. Any such issuance could result in substantial dilution
to our existing shareholders and could cause our share price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
price of&nbsp;our&nbsp;ordinary shares may be volatile.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our ordinary shares has fluctuated in the past. Consequently, the current market price of our ordinary shares may not
be indicative of future market prices, and we may be unable to sustain or increase the value of your investment in our ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
conduct some of our operations in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations
from the Gaza Strip and Israel&rsquo;s war against them, may affect our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters is located in Herzliya, Israel. Because we are incorporated under the laws of the State of Israel, and most of
our officers and fourteen out of sixteen of our employees are residents of Israel, our business and operations are directly affected
by economic, political, geopolitical and military conditions in Israel. Since the establishment of the State of Israel in 1948, a number
of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in the region. These
conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various parts of Israel, which
have negatively affected business conditions in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Hamas terrorists infiltrated Israel&rsquo;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&rsquo;s
border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries,
and Hamas additionally kidnapped many Israeli civilians and soldiers.&nbsp;Following the attack, Israel&rsquo;s security cabinet declared
war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror
attacks. In parallel, border clashes between Israel and the Hezbollah terrorist group on Israel&rsquo;s northern border with Lebanon
intensified and may escalate into a greater regional conflict. In October 2025, a ceasefire was brokered between Israel and Hamas. However,
we cannot predict if and to what extent this ceasefire will remain in effect or upheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, since the commencement of these events, there have been continued hostilities along Israel&rsquo;s northern border with Lebanon
(with the Hezbollah terror organization)&nbsp;and on other fronts from various extremist groups in region, such as the Houthis in Yemen
and various rebel militia groups in Syria and Iraq. In October 2024, Israel began limited ground operations against Hezbollah in Lebanon,
and in November 2024, a ceasefire was brokered between Israel and Hezbollah. In addition, in April 2024 and October 2024, Iran (in concert
with other regional actors) launched direct attacks on Israel involving hundreds of drones and missiles and has threatened to continue
to attack Israel and is widely believed to be developing nuclear weapons. Such attacks may continue due to continuing tensions in the
region. In June 2025, in light of continued nuclear threats and intelligence assessments indicating imminent attacks, Israel launched
a preemptive strike directly targeting military and nuclear infrastructure inside Iran, aimed at disrupting Iran&rsquo;s capacity to
coordinate or launch further hostilities against Israel, as well as to degrade its nuclear program. In response, Iran launched multiple
waves of drones and ballistic missiles at Israeli cities. While most of these attacks were intercepted, several caused civilian casualties
and damage to infrastructure. While a ceasefire was reached between Israel and Iran in June 2025 after 12 days of hostilities, the situation
remains volatile. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah
in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. These situations may potentially escalate
in the future to more violent events which may affect Israel and us. Additionally, Yemeni rebel group, the Houthis, launched series of
attacks on global shipping routes in the Red Sea, causing disruptions of supply chain. These geopolitical developments may adversely
affect our ability to continue carrying out various administrative, research, operational and commercial functions and activities both
in Israel and globally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
hostilities, armed conflicts, terrorist activities involving Israel or the interruption or curtailment of trade between Israel and its
trading partners, or any political instability in the region could directly or indirectly adversely affect business conditions and our
results of operations and could make it more difficult for us to raise capital and could adversely affect the market price of our ordinary
share. An escalation of tensions or violence might result in a significant downturn in the economic or financial condition of Israel,
which could have a material adverse effect on our operations in Israel and our business. Parties with whom we do business have sometimes
declined to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary
in order to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties
with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under
those agreements pursuant to force majeure provisions in such agreements.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israel Defense Force, or IDF, the national military of Israel, is a conscripted military service, subject to certain exceptions. Since
October 7, 2023, the IDF has called up several hundred thousand of its reserve forces to serve. Fourteen out of our current 16 employees
are resident in Israel. Three of our five executive officers and the 11 other non-management employees of the Company reside in Israel.
Currently none of our executive officers nor non-management employees have been called up to perform reserve military service; however,
some employees may be called for service in the current or future wars or other armed conflicts with Hamas, Hezbollah or other regional
threat actors, and such persons may be absent for an extended period of time. As a result, our operations in Israel may be disrupted
by such absences, which disruption may materially and adversely affect our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the war broke out on October 7, 2023, our operations have not been adversely affected by this situation, and we have not experienced
disruptions to our clinical studies. As such, our clinical and business development activities remain on track. However, potential changes
to the security situation in Israel are difficult to predict at this stage. If these ceasefires collapse or if the war expands to other
fronts, such as Iran, Lebanon, Syria and the West Bank, our operations may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our&nbsp;clinical and pre-clinical&nbsp;research and development is&nbsp;currently&nbsp;being conducted outside of Israel,&nbsp;other
than our 12-month open&nbsp;label-extension, or OLE, study of the PARADIGM trial,&nbsp;partially conducted in Tel&nbsp;Aviv,&nbsp;and
a&nbsp;planned&nbsp;Phase 2 trial&nbsp;with PrimeC&nbsp;for&nbsp;AD that we plan to conduct in Haifa, Israel. The OLE has not been affected
by the war, although the quality of the study may be adversely affected if as a result of the war patients are unable to visit the study
center or the study coordinator is not able to conduct home visits and monitor the&nbsp;patients. In addition, in the event of a significant
escalation of hostilities in northern Israel, there may be a delay in the&nbsp;planned&nbsp;AD trial.&nbsp;We do not believe the planned
AD trial will be materially affected by the war and do not anticipate that any such delay as a result of the war would have a material
impact on us. We may also elect to set up a site in Israel for a Phase 3 pivotal ALS trial of PrimeC, but this would be in addition to
numerous other sites in Europe and the United States, and as a result we do not expect the timeline or quality of this trial to be adversely
affected by the war. Our manufacturing is conducted in India. We do not currently anticipate any disruption to the supply chain relevant
to our ongoing clinical trials and believe there are alternative sources of supply from whom we could obtain the necessary finished drug
product to conduct our clinical trials. In addition, we believe we have sufficient finished product in inventory to continue our ongoing
clinical trials for at least the next few months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle
East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by
terrorist attacks or acts of war, there can be no assurance that this government coverage will be maintained, or if maintained, will
be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect
on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior
to October 2023, the Israeli government pursued extensive changes to Israel&rsquo;s judicial system, which sparked extensive political
debate and unrest. Some changes to Israel&rsquo;s judicial system have been made, but to date, the more extensive change have not progressed.
Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the
aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>THE
PRIVATE PLACEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 4, 2025, we entered into the Purchase Agreement with the selling shareholder, pursuant to which we agreed to issue and sell,
in the September 2025 Private Placement 333,334 ordinary shares. The purchase price of each Share was $1.50. The gross proceeds from
the September 2025 Private Placement were approximately $0.5 million, before deducting offering expenses payable by.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, on September 9, 2025 we issued to the purchaser the subscribed for Shares against payment of
$0.5 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, we are registering for resale on this registration statement on Form F-3, 333,334 Shares issued
to the selling shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Shares offered by the selling shareholder for resale pursuant to this prospectus will be sold by the selling shareholder. We will
not receive any of the proceeds from such sales. The selling shareholder will receive all of the proceeds from any sales of the Shares
offered hereby. However, we will incur expenses in connection with the registration of the Shares offered hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_010"></A>MARKET
FOR ORDINARY SHARES AND DIVIDEND POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares are traded on the Nasdaq Capital Market under the symbol &ldquo;NRSN.&rdquo; The last reported sale price of our ordinary
shares on October 27, 2025 on the Nasdaq Capital Market was $1.14 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our ordinary shares, and we anticipate that, for the foreseeable future, we will retain
any future earnings to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay
cash dividends for at least the next several&nbsp;years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of dividends may also be limited by the Israeli Companies Law,&nbsp;5759-1999 (the &ldquo;Companies Law&rdquo;), which permits
the distribution of dividends only out of retained earnings or earnings derived over the two most recent fiscal&nbsp;years, whichever
is higher, provided that there is no reasonable concern that payment of a dividend will prevent a company from satisfying its existing
and foreseeable obligations as they become due. As of December&nbsp;31, 2024, we did not have distributable earnings pursuant to the
Companies Law. Dividend distributions may be determined by our board of directors, as our amended and restated articles of association
do not provide that such distributions require shareholder approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_011"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth our total capitalization:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis as of
    June&nbsp;30, 2025; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a pro forma basis, giving effect to the following events that occurred
after June 30, 2025 (i) the issuance of 1,116,774 ordinary shares that were issued pursuant to the Capital on Demand Sales Agreement,
or the Sales Agreement, entered with JonesTrading Institutional Services LLC on August 16, 2024, or the August 2024 Sales Agreement, for
net proceeds of approximately $1,435,432, and (ii) the issuance of 333,334 ordinary shares for gross proceeds of approximately $0.5
million (before deducting offering expenses payable by us of approximately $28,000) in the September 2025 Private Placement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma amounts shown below are unaudited, represent management&rsquo;s estimate, and their accounting treatment has not been completed.
The information in this table should be read in conjunction with and is qualified by reference to the financial statements and notes
thereto and other financial information incorporated by reference into this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table should be read in conjunction with &ldquo;Use of Proceeds,&rdquo; our financial statements and related notes that are
incorporated by reference into this prospectus and the other financial information included or incorporated by reference into this prospectus.
Our historical results do not necessarily indicate our expected results for any future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30, 2025</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">(unaudited)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual<BR> (in&nbsp;thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma<BR> (in&nbsp;thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">666</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,574</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Long term liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Shareholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Ordinary shares, no par value per share</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Share premium and capital reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,758</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(41,369</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(41,369</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(519</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,389</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total capitalization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(519</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,389</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table above is based on 24,602,405 ordinary shares issued and outstanding as of June 30, 2025. This number excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,129,128 ordinary shares
    issuable upon the exercise of options outstanding, at a weighted average exercise price of $2.21 per share under our 2018 Share Option
    Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000 ordinary shares
    issuable upon the vesting of restricted share units outstanding, some of which are under our 2018 Share Incentive Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,043,863 ordinary shares
    reserved for issuance and available for future grant under our 2018 Share Incentive Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,656,271 ordinary shares
    underlying pre-funded warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,535,000 ordinary shares
    underlying warrants with a weighted average exercise price of $1.83 per share; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Commitment Shares and
    the Advance Shares and any additional shares we may issue to YA pursuant to the Purchase Agreement should we elect to sell such shares
    to YA.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_012"></A>SELLING
SHAREHOLDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ordinary shares being offered by the selling shareholder pursuant to this prospectus are the Shares issued to such selling shareholder.
We are registering the Shares in order to permit the selling shareholder to offer the Shares for resale from time to time. To our knowledge,
the selling shareholder has not had any material relationship with us or our affiliates within the past three&nbsp;years. Our knowledge
is based on information provided by the selling shareholder in connection with the filing of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the selling shareholder and other information regarding the beneficial ownership of the Shares by the selling shareholder.
This table is prepared based on information supplied to us by the selling shareholder. The second column lists the number of our ordinary
shares beneficially owned by the selling shareholder, based on its ownership of our ordinary shares, as of October 27, 2025. The fourth
column lists the maximum number of our ordinary shares that may be sold or otherwise disposed of by the selling shareholder pursuant
to the registration statement of which this prospectus forms a part. The selling shareholder may sell or otherwise dispose of some, all
or none of their Shares in this offering. Pursuant to the rules of the SEC, beneficial ownership includes any of the ordinary shares
as to which a shareholder has sole or shared voting power or investment power, as well as any ordinary shares that a selling shareholder
has the right to acquire within 60&nbsp;days as of the date of this prospectus. The percentage of beneficial ownership for the selling
shareholder is based on 29,550,970 ordinary shares outstanding as of October 27, 2025 and the number of ordinary shares issuable upon
exercise or conversion of convertible securities that are currently exercisable or convertible or are exercisable or convertible within
60&nbsp;days of the date of this prospectus, beneficially owned by the selling shareholder. The fifth and sixth column assumes the sale
of all of the Shares offered by the selling shareholder pursuant to this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Selling Shareholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary <BR> Shares <BR> Beneficially <BR> Owned Prior <BR> to&nbsp;the <BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage&nbsp;of <BR> Outstanding <BR> Ordinary <BR> Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To Be Sold </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>to this </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus </B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Ordinary Shares Beneficially Owned <BR> After&nbsp;the <BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage&nbsp;of <BR> Outstanding <BR> Ordinary <BR> Shares after&nbsp;the <BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lior Tamar Investments Ltd.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">333,334</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1.13</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">333,334</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes that (i) all of
    the Shares covered by the registration statement of which this prospectus is a part are sold in this offering and (ii) the selling
    shareholder does not acquire additional ordinary shares after the date of this prospectus and prior to completion of this offering.
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_013"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling shareholder and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their
securities covered hereby on the Nasdaq Capital Market or any other stock exchange, market or trading facility on which the securities
are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling shareholder may use any one or more
of the following methods when selling securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions
    and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades in which the
    broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate
    the transaction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer
    as principal and the subsequent resale by the broker-dealer for its account;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution
    in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an over-the-counter distribution
    in accordance with the rules of Nasdaq;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through trading plans entered
    into by the selling shareholder pursuant to Rule&nbsp;10b5-1 under the Exchange&nbsp;Act that are in place at the time of an offering
    pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on
    the basis of parameters described in such trading plans;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions other than
    on such exchanges or in the over-the-counter market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">directly to purchasers,
    including through a specific bidding, auction or other process or in privately negotiated transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement of short sales;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions through
    broker-dealers that agree with the selling shareholder to sell a specified number of such securities at a stipulated price per security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing or
    settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any such
    methods of sale; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method permitted
    pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling shareholder may also sell securities under Rule&nbsp;144 or any other exemption from registration under the Securities Act, if
available, rather than under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the selling shareholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling shareholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule&nbsp;2121; and in the case of a principal transaction a markup
or markdown in compliance with FINRA Rule&nbsp;2121.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities or interests therein, the selling shareholder may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The selling shareholder may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The selling shareholder may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling shareholder and any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. The selling shareholder has informed us that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to pay certain fees and expenses incurred by us incident to the registration of the resale of the Shares covered by this
prospectus. We have agreed to indemnify the selling shareholder against certain losses, claims, damages and liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_014"></A>DESCRIPTION
OF OUR SECURITIES BEING REGISTERED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities to be registered for resale on this registration statement on Form&nbsp;F-3 of which this prospectus forms a part include
up to an aggregate amount of 333,334 Shares issued to the selling shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized share capital consists of 90,000,000&nbsp;ordinary shares, no par value per share, of which 29,550,970 ordinary shares were
issued and outstanding as of October 27, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the outstanding ordinary shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not
have any pre-emptive rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights and Conversion</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
ordinary shares will have identical voting and other rights in all respects. None of our major shareholders have different voting rights
than our other shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
of Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully
paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association,
unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares
are listed for trading. The ownership or voting of ordinary shares by non-residents&nbsp;of Israel is not restricted in any way by the
amended and restated articles of association or the laws of the State of Israel, except for ownership by nationals of some countries
that are, or have been, in a state of war with Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liability
to Further Capital Calls</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect
to ordinary shares held by such shareholders, which is not payable at a fixed time. Such shareholder shall pay the amount of every call
so made upon him. Unless otherwise stipulated by our board of directors, each payment in response to a call shall be deemed to constitute
a pro rata payment on account of all shares with respect to which such call was made. A shareholder shall not be entitled to his rights
as shareholder, including the right to dividends, unless such shareholder has fully paid all the notices of call delivered to him, or
which according to our amended and restated articles of association are deemed to have been delivered to him, together with interest,
linkage and expenses, if any, unless otherwise determined by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Business
Combinations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our amended and restated articles of association, we may not engage in any &ldquo;business combinations&rdquo; with any &ldquo;interested
shareholder&rdquo; for a three-year&nbsp;period following the time that such shareholder became an interested shareholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior to the time that
    such shareholder became an interested shareholder, our board of directors approved either the business combination or the transaction
    which resulted in the shareholder becoming an interested shareholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon consummation of the
    transaction which resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of
    our voting shares outstanding at the time the transaction commenced, excluding for purposes of determining our voting shares outstanding
    (but&nbsp;not the outstanding voting shares owned by the interested shareholder) those shares owned by persons who are directors
    and also officers; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the time that such shareholder
    became an interested shareholder, or subsequent to such time, the business combination is approved by our board of directors and
    authorized at a general meeting of shareholders by the affirmative vote of at least 66<SUP>2/3</SUP>% of our voting shares outstanding
    that are not owned by the interested shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
a &ldquo;business combination&rdquo; includes any merger, consolidation, sale or other transaction resulting in a financial benefit to
the interested shareholder. Subject to certain exceptions, an &ldquo;interested shareholder&rdquo; is any person (other than us and any
of our direct or indirect majority-owned&nbsp;subsidiaries) who, together with such person&rsquo;s affiliates and associates, owns, or
within the previous three&nbsp;years owned, 15% or more of our voting shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain circumstances, this provision will make it more difficult for a person who would be an &ldquo;interested shareholder&rdquo; to
effect various business combinations with a corporation for a three-year&nbsp;period. This provision may encourage companies interested
in acquiring us to negotiate in advance with our board of directors because the shareholder approval requirement would be avoided if
our board of directors approves either the business combination or the transaction which results in the shareholder becoming an interested
shareholder. These provisions also may have the effect of preventing changes in our board of directors and may make it more difficult
to accomplish transactions which shareholders may otherwise deem to be in their best interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Election
of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares do not have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting
power represented at a shareholders meeting have the power to elect our directors, subject to the special approval requirements for external
directors under the Companies Law. Under our amended and restated articles of association, the number of directors on our board of directors
must be no less than three and no more than nine, including any external directors required to be appointed under the Companies Law.
The minimum and maximum number of directors may be changed, at any time and from time to time, by a special vote of the holders of at
least 66<SUP>2</SUP>/<SUB>3</SUB>% of the outstanding shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than external directors, for whom special election requirements apply under the Companies Law, the vote required to appoint a director
is a simple majority vote. In addition, under our amended and restated articles of association, our board of directors may elect new
directors to fill vacancies (whether such vacancy is due to a director no longer serving or due to the number of directors serving being
less than the maximum required in our amended and restated articles of association), provided that the total number of directors shall
not, at any time, exceed nine directors and provided that our board of directors may not elect external directors. Our amended and restated
articles of association provide that the term of a director appointed by our board of directors to fill any vacancy will be for the remaining
term of office of the director(s)&nbsp;whose office(s)&nbsp;have been vacated. Furthermore, under our amended and restated articles of
association, our directors, other than external directors, are divided into three classes with staggered three-year&nbsp;terms. Each
class of directors consists, as nearly as possible, of 1/3 of the total number of directors constituting the entire board of directors
(other than the external directors).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">External
directors are elected for an initial term of three&nbsp;years, may be elected for additional three-year&nbsp;terms, and may be removed
from office pursuant to the terms of the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
and Liquidation Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies
Law, dividend distributions are determined by our board of directors and do not require the approval of the shareholders of a company
unless our articles of association provide otherwise. Our amended and restated articles of association do not require shareholder approval
of a dividend distribution and provide that dividend distributions may be determined by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law, subject to certain exceptions with the respect to the buyback by us of our ordinary shares, the distribution amount
is limited to the greater of retained earnings or earnings generated over the previous two&nbsp;years, according to our then last reviewed
or audited financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that
the end of the period to which the financial statements relate is not more than six&nbsp;months prior to the date of the distribution.
If we do not meet such criteria, then the we may distribute dividends only with court approval. In each case, we are only permitted to
distribute a dividend if our board of directors and, if applicable, the court determines that there is no reasonable concern that payment
of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. In the event of our liquidation,
after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to
their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or
distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exchange
Controls</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of
ordinary shares or interest or other payments to non-residents&nbsp;of Israel, except for shareholders who are subjects of certain countries
that are, or have been, in a state of war with Israel at such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shareholder
Meetings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later
than 15&nbsp;months after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders
are referred to in our amended and restated articles of association as special meetings. Our board of directors may call special meetings
whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides
that our board of directors is required to convene a special general meeting upon the written request of (i)&nbsp;any two of our directors
or one-quarter&nbsp;of the members of our board of directors or (ii)&nbsp;one or more shareholders holding, in the aggregate, either
(a)&nbsp;5% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b)&nbsp;5% or more of our outstanding
voting power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors
include a matter in the agenda of a general meeting to be convened in the future, such as nominating a director candidate, provided that
it is appropriate to discuss such a matter at the general meeting. Our amended and restated articles of association contain procedural
guidelines and disclosure items with respect to the submission of shareholder proposals for shareholders meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general
meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and 40&nbsp;days
prior to the date of the meeting. Furthermore, the Companies Law requires that resolutions regarding, among other things, the following
matters must be passed at a general meeting of our shareholders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments to our amended
    and restated articles of association;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment or termination
    of our auditors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">election of directors,
    including external directors (unless otherwise determined in our amended and restated articles of association);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval of certain related
    party transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases or reductions
    of our authorized share capital;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise of our board
    of directors&rsquo; powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any
    of its powers is required for our proper management.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our amended and restated articles of association, we are not required to give notice to our registered shareholders pursuant to the Companies
Law, unless otherwise required by law. The Companies Law requires that a notice of any annual general meeting or special general meeting
be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal
of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, or as otherwise
required under applicable law, notice must be provided at least 35 days prior to the meeting. Under the Companies Law, shareholders of
a public company are not permitted to take action by written consent in lieu of a meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Quorum
Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all
matters submitted to a vote before the shareholders at a general meeting. Under our amended and restated articles of association, the
quorum required for general meetings of shareholders must consist of at least two shareholders present in person or by proxy (including
by voting deed) holding 25% or more of our voting rights. A meeting adjourned for lack of a quorum will generally be adjourned to the
same&nbsp;day of the following week at the same time and place, or to such other&nbsp;day, time or place as indicated by our board of
directors if so specified in the notice of the meeting. At the reconvened meeting, any number of shareholders present in person or by
proxy shall constitute a lawful quorum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Vote
Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless
otherwise required by the Companies Law or by our amended and restated articles of association. Our amended and restated articles of
association provide that all resolutions of our board of directors require a simple majority vote of the directors present and voting
at such meeting, unless otherwise required by the Companies Law or by our amended and restated articles of association. Pursuant to our
amended and restated articles of association, in the event the vote is tied, the chair of the board of directors will have a casting
vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our amended and restated articles of association, an amendment to our amended and restated articles of association regarding any change
of the composition or election procedures of our directors will require a special majority vote (66&frac23;%). In addition, any change
to the rights and privileges of the holders of any class of our shares requires a simple majority of the class so affected (or otherwise
in accordance with the terms of such class), in addition to the simple majority vote of all classes of shares voting together as a single
class at a shareholder meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, each of (i)&nbsp;the approval of an extraordinary transaction with a controlling shareholder and (ii)&nbsp;the terms
of employment or other engagement of the controlling shareholder of the company or such controlling shareholder&rsquo;s relative (even
if not extraordinary) requires the approval of the compensation committee, board of directors, and shareholders, subject to limited exceptions.
Certain transactions with respect to remuneration of our office holders and directors require approvals of the compensation committee,
board of directors, and in the case of the chief executive officer and directors, shareholders, subject to limited exceptions Another
exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement
or reorganization, of the company pursuant to Section&nbsp;350 of the Companies Law, which requires the approval of holders of 75% of
the voting rights represented at the meeting, in person or by proxy and voting on the resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Access
to Corporate Records</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, shareholders are provided access to: minutes of our general meetings; our shareholders register and material shareholders
register; our amended and restated articles of association; our financial statements; and any document that we are required by law to
file publicly with the Israeli Companies&nbsp;Registrar (the &ldquo;ISA&rdquo;). In addition, shareholders may request to be provided
with any document related to an action or transaction requiring shareholder approval under the related party transaction provisions of
the Companies Law. We may deny this request if we believe it has not been made in good faith or if such denial is necessary to protect
our interest or protect a trade secret or patent.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modification
of Class Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law and our amended and restated articles of association, the rights attached to any class of share, such as voting, liquidation
and dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a
separate class meeting, or otherwise in accordance with the terms of such class of shares, in addition to the simple majority vote of
all classes of shares voting together as a single class at a shareholder meeting, as set forth in our amended and restated articles of
association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acquisitions
Under Israeli Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Full
Tender Offer.&nbsp;</I>A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the
target company&rsquo;s issued and outstanding share capital is required by the Companies Law to make a tender offer to all of the company&rsquo;s
shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of an Israeli
public company and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required
to make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding
shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of
the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept
the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However,
a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding
share capital of the company or of the applicable class of shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder
accepted the tender offer or not, may, within six&nbsp;months from the date of acceptance of the tender offer, petition an Israeli court
to determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court.
However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will
not be entitled to petition the Israeli court as described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
(a)&nbsp;the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital
of the company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that
do not have a personal interest in the acceptance of the tender offer or (b)&nbsp;the shareholders who did not accept the tender offer
hold 2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire
shares of the company that will increase its holdings to more than 90% of the company&rsquo;s issued and outstanding share capital or
of the applicable class from shareholders who accepted the tender offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
Tender Offer.&nbsp;</I>The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of
a special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the
company. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender
offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company. These
requirements do not apply if, in general, the acquisition (1)&nbsp;was made in a private placement that received shareholder approval,
(2)&nbsp;was from a 25% or greater shareholder of the company which resulted in the acquirer becoming a 25% or greater shareholder of
the company, or (3)&nbsp;was from a 45% or greater shareholder of the company which resulted in the acquirer becoming a 45% or greater
shareholder of the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
special tender offer must be extended to all shareholders of a company but the offeror is not required to purchase shares representing
more than 5% of the voting power attached to the company&rsquo;s outstanding shares, regardless of how many shares are tendered by shareholders.
A special tender offer may be consummated only if (i)&nbsp;at least 5% of the voting power attached to the company&rsquo;s outstanding
shares will be acquired by the offeror and (ii)&nbsp;the number of shares tendered in the offer exceeds the number of shares whose holders
objected to the offer&nbsp;(excluding the purchaser and its controlling shareholders, holders of 25% or more of the voting rights in
the company or any person having a personal interest in the acceptance of the tender offer or any other person acting on their behalf,
including the relatives and entities under such person&rsquo;s control). If a special tender offer is accepted, then the purchaser or
any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent
tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of
one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the
initial special tender offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Merger.
</I>The Companies Law permits merger transactions if approved by each party&rsquo;s board of directors and, unless certain requirements
described under the Companies Law are met, by a majority vote of each party&rsquo;s shares, and, in the case of the target company, a
majority vote of each class of its shares, voted on the proposed merger at a shareholders meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of
shares represented at the shareholders meeting that are held by parties other than the other party to the merger, or by any person (or
group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint
25% or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company&rsquo;s
own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject
to the same special majority approval that governs all extraordinary transactions with controlling shareholders. See&nbsp;&ldquo;Management&nbsp;&mdash;&nbsp;Approval
of Related Party Transactions under Israeli Law&nbsp;&mdash;&nbsp;Fiduciary Duties of Directors and Officers&nbsp;&mdash;&nbsp;Disclosure
of Personal Interests of an Office Holder and Approval of Certain Transactions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the
exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of
at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value
to the parties to the merger and the consideration offered to the shareholders of the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there
exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging
entities, and may further give instructions to secure the rights of creditors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a merger may not be consummated unless at least 50&nbsp;days have passed from the date on which a proposal for approval of
the merger was filed by each party with the IRC and at least 30&nbsp;days have passed from the date on which the merger was approved
by the shareholders of each party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
tax law treats some acquisitions, such as share-for-share&nbsp;exchanges between an Israeli company and a foreign company, less favorably
than U.S.&nbsp;tax laws. For example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges his ordinary
shares for shares in another corporation to taxation prior to the sale of the shares received in such share-for-share&nbsp;swap.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-Takeover&nbsp;Measures
Under Israeli Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law allows us to create and issue shares having rights different from those attached to ordinary shares, including shares providing
certain preferred rights with respect to voting, distributions or other matters and shares having pre-emptive&nbsp;rights. As of the
date of this prospectus, no preferred shares were authorized under our amended and restated articles of association. In the future, if
we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may
be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential
premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require
an amendment to our amended and restated articles of association, which requires the prior approval of the holders of a majority of the
voting power attaching to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled
to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies
Law as described above in &ldquo;&mdash;&nbsp;Voting Rights.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Borrowing
Powers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law and our amended and restated articles of association, our board of directors may exercise all powers and take all
actions that are not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders,
including the power to borrow money for company purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Changes
in Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions
of the Companies Law and must be approved by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions
that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings
or profits, require the approval of both our board of directors and an Israeli court.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Establishment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the laws of the State of Israel on February&nbsp;13, 2017. We are registered with the IRC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>History
of Share Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
January&nbsp;1, 2022, our issued share capital has changed as provided below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March&nbsp;2022, we issued 645,000&nbsp;ordinary shares upon exercise of warrants issued in our initial public offering at a price per
share of $6.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October&nbsp;2022, we issued 35,980&nbsp;ordinary shares pursuant to vesting of restricted stock units (&ldquo;RSUs&rdquo;) that were
granted to one of our officers in October&nbsp;2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December&nbsp;2022, we issued 72,000&nbsp;ordinary shares pursuant to vesting of RSUs that were granted to our officers in November&nbsp;2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, we issued 85,449&nbsp;ordinary shares to certain consultants in exchange for their services. One of the consultants received 44,000&nbsp;shares
of restricted stock which were issued in 4 equal installments and subject to 2 year lock-up&nbsp;period. The other consultant&rsquo;s
received ordinary shares subject to a 6&nbsp;month lock-up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March, June, September and December 2023, we issued 72,000&nbsp;ordinary shares pursuant to vesting of RSUs that were granted to our
officers in November&nbsp;2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May&nbsp;2023, we issued 3,600&nbsp;ordinary shares for gross proceeds of $7,200 in connection with our at-the-market&nbsp;offering program.
The ordinary shares were sold at market prices at the time of sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May and June 2023 we issued 320,479&nbsp;ordinary shares pursuant to vesting of RSUs that were granted to our officers in March&nbsp;2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June, September, December 2023 and in March 2024, we issued a total of 100,000&nbsp;ordinary shares pursuant to vesting of RSUs that
were granted to our employees in March&nbsp;2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June&nbsp;2023, we issued 126,000&nbsp;ordinary shares pursuant to the exercise of options at an exercise price of $0.033 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June&nbsp;2023, we issued 1,330,000&nbsp;ordinary shares pursuant to a registered direct offering at a price per share of $1.50.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, we issued 1,670,000 ordinary shares pursuant to the exercise of pre-funded&nbsp;warrants that were granted pursuant to
a registered direct offering at a price per share of $0.0001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, we issued 160,000&nbsp;ordinary shares pursuant to vesting of RSUs that were granted to our non-management directors in March
2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March, June, September and December 2024, we issued 72,000&nbsp;ordinary shares pursuant to vesting of RSUs that were granted to our
officers in November&nbsp;2021. In April 2024, we issued 20,000&nbsp;ordinary shares pursuant to vesting of RSUs that were granted
to our officers in April&nbsp;2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, we issued 1,732,000 ordinary shares pursuant to a registered direct offering at a price per share of $1.50.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, we issued 70,964 ordinary shares to our placement agent as partial consideration in exchange for their services, in connection
with a registered direct offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, we issued 632,000 ordinary shares pursuant to the exercise of pre-funded&nbsp;warrants that were granted pursuant to a registered
direct offering at a price per share of $0.0001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, we issued 616,000 ordinary shares pursuant to the exercise of pre-funded&nbsp;warrants that were granted pursuant to a registered
direct offering at a price per share of $0.0001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, we issued 800,000 ordinary shares pursuant to a private placement offering at a combined purchase price of $0.75 per share
and accompanying warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October and November 2024 we issued 48,000 ordinary shares pursuant to vesting of RSUs that were granted to service providers in May
2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following our entry into
the Standby Equity Purchase Agreement in October 2024, as of the date hereof we issued an aggregate of 399,697 ordinary shares to YA,
consisting of (i) 224,697 Commitment Shares that we issued to YA as consideration for YA&rsquo;s irrevocable commitment to purchase our
ordinary shares, and (ii) 175,000 ordinary shares that we sold to YA as Advance Shares.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2024, we issued
2,343,729 ordinary shares, 1,656,271 pre-funded warrants and warrants to purchase 8,000,000 ordinary shares in a private placement. The
purchase price of each ordinary share and accompanying warrants was $1.25, and the purchase price of each pre-funded warrant and accompanying
warrants was $1.2499. In September and October 2025, an aggregate of 1,380,000 December 2024 Pre-Funded Warrants have been exercised.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025 we issued 295,512 ordinary shares pursuant to vesting of RSUs that were granted to service providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April and June, 2025, we issued (i) 14,000 ordinary shares pursuant to the exercise of options at an exercise price of $0.96, and (ii)
160,000 ordinary shares pursuant to vesting of RSUs that were granted to our directors in 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2025, we issued 20,000 ordinary shares pursuant to vesting of RSUs that were granted to our officers in April 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In September 2025, we issued
333,334 ordinary shares pursuant to the September 2025 Private Placement. The purchase price of each ordinary share was $1.50.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In October 2025, we issued
(i) 9,000 ordinary shares pursuant to the exercise of options at an exercise price of $0.96, and (ii) an aggregate number of 2,109,457
restricted shares to certain officers and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of the date hereof,&#8239;we
issued an aggregate of 2,931,235 ordinary shares pursuant to the August 2024 Sales Agreement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar of Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our ordinary shares is American Stock Transfer&nbsp;&amp; Trust Company, LLC. Its address is 6201 15<SUP>th</SUP>&nbsp;Avenue,
Brooklyn, New&nbsp;York 11219, and its telephone number is (800)&nbsp;937-5449.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_015"></A>EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the estimated expenses of this offering payable by us with respect to the issuance and distribution of the securities covered
by the registration statement of which this prospectus forms a part. With the exception of the SEC registration fee, all amounts are
estimates and may change:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">53</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Printer fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Accountants&rsquo; fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Miscellaneous</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">956</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">28,009</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_016"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal matters with respect to Israeli law and with respect to the validity of the offered securities under Israeli law will be passed
upon for us by Goldfarb Gross Seligman&nbsp;&amp; Co. Certain legal matters with respect to U.S.&nbsp;law will be passed upon for us
by Greenberg Traurig, P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_017"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of NeuroSense Therapeutics Ltd. as of December 31, 2024 and 2023 and for each of the years in the three-year
period ended December 31, 2024 have been incorporated by reference herein in reliance upon the report of Somekh Chaikin, a member firm
of KPMG International, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said
firm as experts in accounting and auditing. The audit report covering the December 31, 2024 consolidated financial statements contains
an explanatory paragraph that states that the Company&rsquo;s recurring losses and its expectation to incur significant additional losses
raise substantial doubt about the entity&rsquo;s ability to continue as a going concern. The consolidated financial statements do not
include any adjustments that might result from the outcome of that uncertainty.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_018"></A>ENFORCEMENT
OF CIVIL LIABILITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli
experts named in this prospectus, substantially all of whom reside outside the U.S., may be difficult to obtain within the U.S. Furthermore,
because substantially all of our assets and substantially all of our directors and officers are located outside the U.S., any judgment
obtained in the U.S. against us or any of our directors and officers may not be collectible within the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have irrevocably appointed Cogency Global Inc. as our agent to receive service of process in any action against us in any U.S.&nbsp;federal
or state court arising out of this offering or any purchase or sale of securities in connection with this offering. The address of our
agent is 122 East 42<SUP>nd</SUP>&nbsp;Street, 18<SUP>th</SUP>&nbsp;Floor, New&nbsp;York, NY&nbsp;10168.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been informed by our legal counsel in Israel, Goldfarb Gross Seligman&nbsp;&amp; Co., that it may be difficult to initiate an action
with respect to U.S.&nbsp;securities law in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S.&nbsp;securities
laws reasoning that Israel is not the most appropriate forum to hear such a claim. In addition, even if an Israeli court agrees to hear
a claim, it may determine that Israeli law and not U.S.&nbsp;law is applicable to the claim. If U.S.&nbsp;law is found to be applicable,
the content of applicable U.S.&nbsp;law must be proved as a fact by expert witnesses which can be a time-consuming&nbsp;and costly process.
Certain matters of procedure may also be governed by Israeli law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain time limitations and legal procedures, Israeli courts may enforce a U.S.&nbsp;judgment in a civil matter which, subject to
certain exceptions, is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange&nbsp;Act
and including a monetary or compensatory judgment in a non-civil&nbsp;matter, provided that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was rendered
    by a court which was, according to the laws of the state of the court, competent to render the judgment;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the obligation imposed
    by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of
    the judgment is not contrary to public policy; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is executory
    in the state in which it was given.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if these conditions
    are met, an Israeli court will not declare a foreign civil judgment enforceable if:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was given
    in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the enforcement of the
    judgment is likely to prejudice the sovereignty or security of the State of Israel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was obtained
    by fraud;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the opportunity given to
    the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli court;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was rendered
    by a court not competent to render it according to the laws of private international law as they apply in Israel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is contradictory
    to another judgment that was given in the same matter between the same parties and that is still valid; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the time the action
    was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal
    in Israel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into
non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a
non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange
in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of
the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest
at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable
exchange rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_019"></A>WHERE
CAN YOU FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of the registration statement on Form&nbsp;F-3 we have filed with the SEC under the Securities Act, with respect to
the securities offered by this prospectus. However, as is permitted by the rules and regulations of the SEC, this prospectus, which constitutes
part of the registration statement, omits certain non-material information, exhibits, schedules and undertakings set forth in the registration
statement. For further information about us, and the securities offered by this prospectus, please refer to the registration statement
and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this
prospectus or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making
an offer of these securities in any state where the offer is not permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the reporting requirements of the Exchange&nbsp;Act that are applicable to a foreign private issuer. In accordance with
the Exchange&nbsp;Act, we file reports, including annual reports on Form&nbsp;20-F by April&nbsp;30<SUP>th</SUP> of each year. We also
furnish to the SEC under cover of Form&nbsp;6-K material information required to be made public in Israel, filed with and made public
by any stock exchange or distributed by us to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers, such
as us, that file electronically with the SEC (<I>http://www.sec.gov</I>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a foreign private issuer, we are exempt from the rules under the Exchange&nbsp;Act prescribing the furnishing and content of proxy statements
to shareholders and our officers, directors and principal shareholders are exempt from the &ldquo;short-swing profits&rdquo; reporting
and liability provisions contained in Section&nbsp;16 of the Exchange&nbsp;Act and related Exchange&nbsp;Act rules.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_020"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; the information we file with it, which means that we can disclose important information
to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus and
information we file later with the SEC will automatically update and supersede this information. The documents we are incorporating by
reference as of their respective dates of filing are:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025029464/ea0237295-20f_neuro.htm">Form 20-F</A> for the fiscal year ended December 31, 2024, filed with the SEC on April 7, 2025;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Reports on Form 6-K
    filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025029491/ea0237424-6k_neuro.htm">April 7, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025034825/ea0239404-6k_neuro.htm">April 24, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025040433/ea0241207-6k_neurosense.htm">May 7, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025058086/ea0247095-6k_neurosense.htm">June 26, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025062549/ea0248532-6k_neurosense.htm">July 10, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025070315/ea0250843-6k_neurosense.htm">August 1, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025078783/ea0254016-6k_neurosense.htm">August 20, 2025</A>,
    <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025079411/ea025405001-6k_neuro.htm">August 21, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025082945/ea0255499-6k_neurosense.htm">September 2, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025084292/ea0255987-6k_neurosense.htm">September 4, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025084296/ea0255994-6k_neurosense.htm">September 4, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025086488/ea0256864-6k_neurosense.htm">September 10, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025091410/ea0258753-6k_neurosense.htm">September 25, 2025</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390025096310/ea0260357-6k_neuro.htm">October 6, &nbsp;2025</A>
    (in each case, to the extent expressly incorporated by reference into our effective registration statements filed by us under the
    Securities Act); and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our
    ordinary shares contained under the heading &ldquo;Item&nbsp;1. Description of Registrant&rsquo;s Securities to be Registered&rdquo;
    in our registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390021060442/ea150948-8a12b_neurosense.htm">Form 8-A</A>, as filed with the SEC on November&nbsp;18, 2021, including any subsequent amendment or
    any report filed for the purpose of updating such description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
subsequent annual reports filed by us pursuant to the Exchange Act on Form 20-F prior to the termination of an offering shall be deemed
to be incorporated by reference to this prospectus and to be a part hereof from the date of filing of such documents. We may also incorporate
part or all of any Form 6-K subsequently submitted by us to the SEC prior to the termination of an offering by identifying in such Forms
6-K that they, or certain parts of their contents, are being incorporated by reference herein, and any Forms 6-K so identified shall
be deemed to be incorporated by reference in this prospectus and to be a part hereof from the date of submission of such documents. Any
statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also
is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified
or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information we incorporate by reference is an important part of this prospectus, and later information that we file with the SEC will
automatically update and supersede the information contained in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide each person, including any beneficial owner to whom a prospectus is delivered, without charge, upon a written or oral request,
a copy of any of the documents incorporated by reference in this prospectus, other than exhibits to such documents which are not specifically
incorporated by reference into such documents. Please direct your written or telephone requests to NeuroSense Therapeutics Ltd., 11 HaMenofim
Street, Building B, Herzliya, 4672562, Israel, Attn: Or Eisenberg, telephone number +972587531153. You may also obtain information about
us by visiting our website at <I>www.neurosense-tx.com</I>. Information contained in our website is not part of this prospectus.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>333,334
Ordinary Shares </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Part&nbsp;II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN THE PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;8.
Indemnification of Directors and Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exculpation,
Insurance and Indemnification of Directors and Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company
may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a
result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our
amended and restated articles of association include such a provision. A company may not exculpate in advance a director from liability
arising from a breach of his or her duty of care in connection with a prohibited dividend or distribution to shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
permitted under the Companies Law, our amended and restated articles of association provide that we may indemnify an office holder in
respect of the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either in
advance of an event or following an event:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a monetary liability incurred
    by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed
    as judgment or arbitrator&rsquo;s decision approved by a competent court. However, if an undertaking to indemnify an office holder
    with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of
    the board of directors, can be foreseen based on the company&rsquo;s activities when the undertaking to indemnify is given, and to
    an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking
    shall detail the abovementioned foreseen events and amount or criteria;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses,
    including reasonable attorneys&rsquo; fees, which were incurred by the office holder as a result of an investigation or proceeding
    filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation
    or proceeding was either (i)&nbsp;concluded without the filing of an indictment against such office holder and without the imposition
    on him of any monetary obligation in lieu of a criminal proceeding, (ii)&nbsp;concluded without the filing of an indictment against
    the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense
    that does not require proof of criminal intent or (iii)&nbsp;in connection with a monetary sanction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses,
    including attorneys&rsquo; fees, incurred by the office holder or which were imposed on the office holder by a court (i)&nbsp;in
    a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii)&nbsp;in connection with criminal
    indictment of which the office holder was acquitted or (iii)&nbsp;in a criminal indictment for which the office holder was convicted
    of an offense that does not require proof of criminal intent;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses he or she incurs
    as a result of administrative proceedings that may be instituted against him or her under Israeli securities laws, if applicable,
    and payments made to injured persons under specific circumstances thereunder; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other matter in respect
    of which it is permitted or will be permitted under applicable law to indemnify an office holder in the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
permitted under the Companies Law, our amended and restated articles of association provide that we may insure an office holder against
the following liabilities incurred for acts performed by him or her as an office holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of
    loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would
    not harm the company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care
    to the company or to another person, to the extent such a breach arises out of the negligent conduct of the office holder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a monetary liability imposed
    on the office holder in favor of a third party;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses he or she incurs
    as a result of administrative proceedings that may be instituted against him or her under the Israeli securities laws if applicable,
    and payments made to injured persons under specific circumstances thereunder; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other matter in respect
    of which it is permitted or will be permitted under applicable law to insure the liability of an office holder in the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of
    loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office
    holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care
    committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an act or omission committed
    with intent to derive illegal personal benefit; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fine or forfeit levied
    against the office holder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the
board of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which controlling
shareholders have a personal interest, also by the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted
or to be permitted by law. Our office holders are currently covered by a directors&rsquo; and officers&rsquo; liability insurance policy.
As of the date of this prospectus, no claims for directors&rsquo; and officers&rsquo; liability insurance have been filed under this
policy and we are not aware of any pending or threatened litigation or proceeding involving any of our office holders, including our
directors, in which indemnification is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into agreements with each of our current office holders exculpating them from a breach of their duty of care to us to the
fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by
law, including, with respect to liabilities resulting from this offering, to the extent that these liabilities are not covered by insurance.
This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable
by the board of directors based on our activities. The maximum aggregate amount of indemnification that we may pay to our office holders
based on such indemnification agreement is the greater of (i)&nbsp;an amount equal to 25% of our shareholders&rsquo; equity on a consolidated
basis, based on our most recent financial statements made publicly available before the date on which the indemnity payment is made,
and (ii)&nbsp;$25&nbsp;million. Such indemnification amounts are in addition to any insurance amounts. These indemnification agreements
supersede all previous letters of indemnification that we have provided to him or her in the past, if any. However, in the opinion of
the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;9.
Exhibits </B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.5pt; text-indent: -23.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;no.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 89%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1#</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1875091/000121390021058163/ff12021a2ex3-2_neurosense.htm">Amended and Restated Articles of Association (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form F-1/A, filed with the SEC on December 6, 2021)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390025084292/ea025598701ex10-1_neuro.htm">Form of Securities Purchase Agreement (filed as Exhibit 10.1 to our Report on Form 6-K furnished to the Securities and Exchange Commission on September 4, 2025 and incorporated herein by reference).</A> &nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ea026263001ex5-1_neurosense.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Goldfarb Gross Seligman&nbsp;&amp; Co., Israeli counsel to the Registrant.</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea026263001ex23-1_neurosense.htm">Consent of Somekh Chaikin (Member firm of KPMG International), Independent Registered Public Accounting Firm</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ea026263001ex5-1_neurosense.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Goldfarb Gross Seligman&nbsp;&amp; Co. (included in Exhibit 5.1).</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#toc">Powers of Attorney (included on signature page to Registration Statement).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ea026263001ex-fee_neurosense.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    Fee Table.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">English translation of
    original Hebrew document.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;10.
Undertakings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant
    hereby undertakes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to file, during any period
    in which offers or sales are being made, a post-effective amendment to this Registration Statement:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to include any prospectus
    required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act&nbsp;of&nbsp;1933 (&ldquo;the Securities Act&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to reflect in the prospectus
    any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment
    thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration
    Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of
    securities offered would not exceed that which was registered)
    and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed
    with the Securities and Exchange Commission pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes in volume and price
    represent no more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo;
    table in the effective registration statement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to include any material
    information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change
    to such information in this Registration Statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, for the purpose of
    determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
    relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona
    fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to remove from registration
    by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to file a post-effective
    amendment to the registration statement to include any financial statements required by Item&nbsp;8.A. of Form&nbsp;20-F at the start
    of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section&nbsp;10(a)(3)&nbsp;of
    the Securities Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment,
    financial statements required pursuant to this paragraph (1)(d)&nbsp;and other information necessary to ensure that all other information
    in the prospectus is at least as current as the date of those financial statements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, for the purpose of
    determining any liability under the Securities Act to any purchaser each prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;as part
    of a registration statement relating to an offering, other than registration statements relying on Rule&nbsp;430B or other than prospectuses
    filed in reliance on Rule&nbsp;430A, shall be deemed to be part of and included in the registration statement as of the date it is
    first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part
    of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
    or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
    use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
    statement or made in any such document immediately prior to such date of first use.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, for the purpose of
    determining liability of a registrant under the Securities Act to any purchaser in the initial distribution of the securities, the
    undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
    statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
    to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and
    will be considered to offer or sell such securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any preliminary prospectus
    or prospectus of the undersigned registrant to the offering required to be filed pursuant to Rule&nbsp;424;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any free writing prospectus
    relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by an undersigned registrant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the portion of any other
    free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities
    provided by or on behalf of the undersigned registrant; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other communication
    that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification
    for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant
    pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification
    is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
    against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
    person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
    person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has
    been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by
    it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="toc"></A>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it complies with all
of the requirements for filing on Form&nbsp;F-3&nbsp;and has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in Herzliya, Israel on&nbsp;October 28, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEUROSENSE THERAPEUTICS LTD.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Or Eisenberg</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, each director and officer whose signature appears below constitutes and appoints, Mr.&nbsp;Alon Ben-Noon
and Mr.&nbsp;Or Eisenberg, and each of them, individually, as his or her true and lawful attorney-in-fact and agent, with full power
of substitution and re-substitution, to sign in any and all capacities any and all amendments or post-effective amendments to this registration
statement on Form&nbsp;F-3, and to sign any and all additional registration statements relating to the same offering of securities of
the Registration Statement that are filed pursuant to Rule&nbsp;462(b)&nbsp;of the Securities Act, and to file the same with all exhibits
thereto and other documents in connection therewith with the Securities and Exchange Commission, granting such attorney-in-fact and agent
full power and authority to do all such other acts and execute all such other documents as he may deem necessary or desirable in connection
with the foregoing, as fully as the undersigned may or could do in person, hereby ratifying and confirming all that such attorney-in-fact
and agent may lawfully do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act, this registration statement has been signed below by the following persons on the dates and
in the capacities indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark Leuchtenberger</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 28, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Leuchtenberger</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alon Ben-Noon</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 28, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Ben-Noon</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer and Director)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Or Eisenberg</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief&nbsp;Financial&nbsp;Officer&nbsp;(Principal&nbsp;Financial&nbsp;Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 28, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Principal Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Revital
    Mandil-Levin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 28, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revital Mandil-Levin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Cary Claiborne</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">External Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 28, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cary Claiborne</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Christine
    Pellizzari</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">External Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 28, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christine Pellizzari</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Roy Golan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">External Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 28, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roy Golan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Signature
of authorized representative in the United&nbsp;States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act&nbsp;of&nbsp;1933, as amended, the Registrant&rsquo;s duly authorized representative has signed
this Registration Statement on Form&nbsp;F-3 on this 28<SUP>th</SUP> day of October, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cogency Global Inc.,</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized U.S. Representative</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Colleen A. De Vries</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colleen A.&nbsp;De Vries</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr. Vice-President, Authorized<BR>
    U.S.&nbsp;Representative&nbsp;&mdash;&nbsp;Cogency Global</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


























































































































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea026263001ex5-1_neurosense.htm
<DESCRIPTION>OPINION OF GOLDFARB GROSS SELIGMAN & CO., ISRAELI COUNSEL TO THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 283.5pt">Tel Aviv, October 28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 283.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">NeuroSense Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">11 HaMenofim Street, Building B<BR>
Herzliya 4672562</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: 28.35pt"><B>Re: <U>NeuroSense Therapeutics
Ltd.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">We have acted as Israeli
counsel to NeuroSense Therapeutics Ltd., an Israeli company organized under the laws of the State of Israel (the &ldquo;Company&rdquo;),
in connection with the preparation and filing of a Registration Statement on Form F-3 (the &ldquo;Registration Statement&rdquo;) under
the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), to be filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;).
The Registration Statement relates to the proposed resale by the selling shareholder named in the Registration Statement of up to an aggregate
of 333,334 ordinary shares, no par value per share of the Company (the &ldquo;Shares&rdquo;). The Shares may be sold from time to time
as set forth in the Registration Statement and the prospectus contained therein (the &ldquo;Prospectus&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">In connection with this
opinion, we have examined and relied upon the Registration Statement, the Company&rsquo;s Amended and Restated Articles of Association,
and such statutes, regulations, corporate records, documents, certificates and such other instruments that we have deemed relevant and
necessary for the basis of our opinion hereinafter expressed. In such examination, we have assumed: (i)&nbsp;the authenticity of original
documents and the genuineness of all signatures; (ii)&nbsp;the conformity to the originals of all documents submitted to us as copies;
(iii)&nbsp;the truth, accuracy and completeness of the information, representations and warranties contained in the corporate records,
documents, certificates and instruments we have reviewed; (iv)&nbsp;the due execution and delivery of all documents where due execution
and delivery are a prerequisite to the effectiveness thereof; and (v)&nbsp;the legal capacity of all natural persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">We are members of the Israel
Bar, and we express no opinion as to any matter relating to the laws of any jurisdiction other than the laws of the State of Israel and
have not, for the purpose of giving this opinion, made any investigation of the laws of any other jurisdiction than the State of Israel.
The opinion set forth herein is made as of the date hereof. We assume no obligation to revise or supplement this opinion to reflect any
changes of law or fact that may occur after the date hereof. This opinion is expressly limited to the matters set forth above, and we
render no opinion, whether by implication or otherwise, as to any other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">On the basis of the foregoing,
and in reliance thereon, we are of the opinion that the Shares have been duly authorized by the Company and are validly issued, fully
paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">We hereby consent to the
filing of this opinion as Exhibit 5.1 to the Registration Statement and to the use of our name under the caption &ldquo;Legal Matters&rdquo;
in the Prospectus. In giving such consent, we do not admit that we are &ldquo;experts&rdquo; within the meaning of such term as used in
the Securities Act, or the rules and regulations of the Commission issued thereunder with respect to any part of the Registration Statement,
including this opinion as an exhibit or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 255.15pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">/s/ Goldfarb Gross Seligman &amp; Co.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Goldfarb Gross Seligman &amp; Co.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 255.15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 255.15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 255.15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 255.15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_002.jpg" ALT=""></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea026263001ex23-1_neurosense.htm
<DESCRIPTION>CONSENT OF SOMEKH CHAIKIN (MEMBER FIRM OF KPMG INTERNATIONAL), INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the use of our report dated April 7, 2025, with respect to the consolidated financial statements of NeuroSense Therapeutics
Ltd., incorporated herein by reference and to the reference to our firm under the heading &ldquo;Experts&rdquo; in the prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Somekh Chaikin</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member Firm of KPMG International</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel Aviv, Israel</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 28, 2025</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ea026263001ex-fee_neurosense.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Template (c) 2024-2025 Novaworks, LLC -->
<!-- Field: Set; Name: AliasFileType; Value: Forms View; Template: Fee Exhibit\Fee Exhibit FE.xds -->
<!-- Field: Set; Name: Platform; Value: Novaworks Fee Exhibit Editor; Version: 1.3a -->
<!-- Field: Set; Name: Control; Value: VGVtcGxhdGU6IChkZWZhdWx0KQ0KQmFzZSBGb250OiBUaW1lcyBOZXcgUm9tYW4sIFRpbWVzLCBTZXJpZg0KQ2FwdGlvbiBTaXplOiAxMnB0DQpUYWJsZSBUaXRsZSBTaXplOiAxMXB0DQpUYWJsZSBIZWFkIFNpemU6IDhwdA0KVGFibGUgQm9keSBTaXplOiAxMHB0 -->
<!-- Field: Set; Name: MD5; Value: c55f5a8613ef1706803700bdd8031f26 -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
  <title>Filing Fee Exhibit</title>
  <meta http-equiv="Content-Type" content="text/html"/>
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">

<div style="display: none">
  <ix:header>
    <ix:hidden>
      <ix:nonNumeric name="ffd:SubmissnTp" contextRef="c_report" id="fee_001">F-3</ix:nonNumeric>
      <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="c_report" id="fee_002">EX-FILING FEES</ix:nonNumeric>
      <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="c_report" id="fee_003">0001875091</ix:nonNumeric>
      <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="c_report" xs:nil="true" id="fee_004"></ix:nonNumeric>
      <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="c_report" id="fee_005">N/A</ix:nonNumeric>
      <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="c_report" id="fee_006">N/A</ix:nonNumeric>
      </ix:hidden>
    <ix:references>
      <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
      </ix:references>
    <ix:resources>
      <xbrli:context id="c_offering_1">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-10-28</xbrli:startDate>
          <xbrli:endDate>2025-10-28</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_report">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-10-28</xbrli:startDate>
          <xbrli:endDate>2025-10-28</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:unit id="USD">
        <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="pure">
        <xbrli:measure>xbrli:pure</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="shares">
        <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unit>
      </ix:resources>
    </ix:header>
  </div>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: right">Ex-Filing Fees</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">CALCULATION OF FILING FEE TABLES</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center"><ix:nonNumeric name="ffd:FormTp" contextRef="c_report" id="fee_007">F-3</ix:nonNumeric></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="c_report" id="fee_008">NeuroSense Therapeutics Ltd.</ix:nonNumeric></p>

<p style="font: bold 11pt Times New Roman, Times, Serif; border-top: Gray 3pt double; padding-top: 6pt; text-align: center; margin-top: 0pt; margin-bottom: 4pt">Table 1: Newly Registered and Carry Forward Securities</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font-size: 2pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="width: 12%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 6.5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="border-bottom: Black 1pt solid">Line Item Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Class Title</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Notes</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Calculation<br/> Rule</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Amount Registered</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Proposed Maximum Offering<br/> Price Per Unit</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Maximum Aggregate Offering Price</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Rate</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Amount of Registration Fee</td></tr>
<tr style="font-size: 2pt; vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="22" style="padding-top: 2pt; font-style: italic; text-align: center; padding-bottom: 2pt">Newly Registered Securities</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_1" format="ixt:booleanfalse" id="fee_009">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_1" id="fee_010">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_1" id="fee_011">Ordinary shares, no par value per share</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(1)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_1" format="ixt:booleantrue" id="fee_012">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="shares" decimals="0" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_013">333,334</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_014">1.15</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_015">383,334.10</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_016">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_017">52.94</ix:nonFraction></td></tr>
<tr style="font-size: 4pt; vertical-align: top; text-align: left">
  <td style="width: 11%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Offering Amounts:</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_018">383,334.10</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_019">52.94</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fees Previously Paid:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fee Offsets:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 1pt solid">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_020">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Net Fee Due:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 3pt double">$</td>
  <td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction name="ffd:NetFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_021">52.94</ix:nonFraction></td></tr>
</table>

<p style="font: bold 8pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 6pt">__________________________________________<br/>
Offering Note(s)</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_1" id="fee_022">Pursuant to Rule 416(a) under the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the securities being registered hereunder also include such indeterminable number of additional securities as may from time to time be issued after the date hereof as a result of share splits, share dividends, recapitalizations or similar transactions.<br/><br/>Represents 333,334 ordinary shares, no par value per share (the &#8220;Ordinary Shares&#8221;), of NeuroSense Therapeutics Ltd. (the &#8220;Company&#8221;), issued in a private placement to the selling shareholder identified in the registration of which this exhibit forms a part. The Company will not receive any proceeds from the sale of its Ordinary Shares by the selling shareholder.<br/><br/>Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated under the Securities Act, as amended, based on the average of the equivalent high ($1.18) and low ($1.12) sales prices of the Ordinary Shares on the Nasdaq Capital Market on October 27, 2025.</ix:nonNumeric></td></tr>
  </table>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ", D8# 2(  A$! Q$!_\0
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MSN_B/^RK\0_[+M_M.L^$%L/&]G;P<EO^$;N1+JN?3&A7%\3GOS@XXX\=4JK
MX]X?=1NK*[;BT].J^%Z^O>Q\#XD/,X<$\05\GNLTIY=[2+2;O_9S^O)62;^P
M]KZ::ZH^CO@C\=? GQ_\!:5X_P# >HC4]*OX1Y\!*K?:7? +OT[4[0$LDB$D
M, >FTJ><CW,L-@8\%L ^YX&/;/%?Q@_ #]HOXD_LX>+AXK^'^J_Z-.5;Q%X8
MU,E?#WB>Q&2K:HPP58'_ )G =B0=RE@?Z7OV9/VX?A'^TOIUK#HVI0^'/'_V
M8?VIX#\0:A;0ZO <'+:<H"KK"@#)ETXD9R6"X!/EY3GF&QB]C7:51:6>VG9.
M2W?2UT]KIV7YCX1^//#G&^&CDV<SCDW%-.U.4*DHPCGKA[G-@')QUDXOFB[:
MWY=['W:.@Q12*P(!!!R >#2U] ?T6FK)]+?U_5PHHR#T.:*!A129!Z$'\:6@
M HHHH **** "BBB@"$QY7&<'T^G;_/\ ]>F8$0.SG'H.3S^/3VZ_C4[]#_GN
M*\Z\8?$?P1X'BM)O%WC3POX0BNN+:3Q-KVD^'ENR.H4ZT\9)&"".O&#C(HMZ
M?-I?FT<N)Q.%P<7B<5*,4M.:4HQBK[OFDXK\5_EZ'\F.G/IS4)C0?\LF_P _
MA_\ 6]Z\23]H[X"O_P UG^%"=02/B+X/_P#ES^0Z?I7M$%Q!<1[X)!(!Z<YZ
MXY!Q^>*+K:\7Z2BW\[2=OG8QPN9Y?CG; YE1J2=[PIU:=1Z;^[&I)JVSTZ%_
MI1132Z@$YZ>QH.^Z75;>7;_@$&Z/V_[]K1NC]O\ OVM>+:C\?_@OI>H7>E:O
M\6/AUI>I:?<_9KK3-3\;:!8:I9WX_P"76\LVU!65NAVGZ8..*_\ PTA\!_\
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MVDG+:BV8_$Y/1F4+*0 OF  8_:SX)_ME_ /X_16R>!O&^F)KEP/.;P=KTO\
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M"G.HHRBYP;]V,DFTKZ<C5O0_8> YAB/JB]?I3T^Z/Q_F:CA&V*.,]1& ?7@
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M@&OS*_:V_95\8_LN>.AI&H1W&K>!=;O_ +3X*\7?9<FZL>,Z!XBR 3K@/0@
M,I##Y2*_5S]GJ42?\%5_VF$]? &I@>N6U3P$!CMQG/4_45^FGQH^#'@SXX>
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MQ_\ P3DT31/$?[9?P>TSQ#IUIJ]AGQM<^1?6POK.'4-(\'^(]7\/W8R",X/
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M]%IHV7:CE_U;_P"Z:D^O^34<O^J?_=-:O5/S3_)GK3^"?^"7_I$C\,_V=]1
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M(O-0V>#YM9U>[TBWN1!9Z]H_]HJ/$6F-P06.A^H/RX&#BOT/@+AS&Y^LOR?
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M@:KH+8[\'4E^EKC)RHK^;WXQ237GQ?\ BO--C[5<?$7Q_P#:B/;71R.>>/\
M'':OZ*_^"//@#4?"_P"S=KOC+5+:XA;XE^.M0U/33=D9N](TG;HXU(]\M?6F
MJD8[@<X;%?AI^VS\-]0^%W[5'QD\/W,,4-AJOC'6/&.A>40<:#XN_P")MI@S
MWVNI!]P>E>'X8XS)<'XO>)& PK@U4YW!1<>7GC5;JI6]UM3F[J*=M;V=SV_$
MC#9IC/"GPZQ6*4O=LI-\UTN5J+E?57BE9R>ME;30_4'_ ((UZ1X&\8>$OC1X
M=\2^&/#'B#5- \1>&=9MO[;T;0-5U3[!XDTO5=H)*/C/]DG!XZ],'C]M(O@O
M\*B^[_A6_@1T[#_A$M P,?6Q_GZ<#K7\D/[$W[3=U^RU\9K3QC=QW%[X*U^V
M'ACQKIEODWPL%(8:[I6",KX>/#KD9!P3S7]:'PO^-?PR^+>A6_B'P%XT\-^)
M=-N+&&Z,FE:S:SWMH"I.=5TH;I-(;@X%^%<G P."?ROQLR/B3*N,<PS./UG^
MRLWDJL'3E7]G!J,(.%J4^2.D5)1G&*DYMIW33_4/!G-^&LTX6R_+<1[%9IE+
M:E[3V:E)7=G>:N]WU>R[EY_@W\)\D_\ "M_ F.F1X2T'^EB?T_0UWFG6.GZ5
M916.FVD%C8P1B.W@@M?L5E"!R!@8 'I@>O<Y'RC^T?\ ME_!K]FO0-0U+Q=X
MET_4/$ MY_[+\%Z)?B]\2:U?! !:VMH&<Z4=Q/,A08.1N9?F[_\ 9F^*OBCX
MR_!7P/\ $WQ7X3M_!6K^,-(&O'P_!="\@LM.O;ACI1%V ,LVC"T9CZL2.F*_
M(<;@<^CET<QS!UUEC?+3]O*O[TN5O]U&O/WE9:RA#E[-J[/UO YKPT\WEEN7
M*B\SLW+V4:;LK?;E2B[7_O25^JU/YIO^"JW_ ">U\2/^Q3^&?_J*25B_\$P_
M^3X?@O\ ]>_CC_U6/B.MG_@JE_R>U\2?^Q2^&G_J(O6/_P $Q/\ D^+X+?\
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MY\3^%<9)4_,O?J*_+#_EIY'_ "]?_6Q]?UZ?E7]I_P"S!^TW\/\ ]JSX=_\
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M_P""/MGX/UOXV?$?PMXKT32=;_M3P"-7TRSU_1M!O?\ 1]*UW2%W<JX)0L&
M9=N0,D '/GW_  5?^&MWX*_:QU?Q6(Q'HWQ.\/>&_$FCWJ]/[1T31&T;5@?<
M#2,$>OB,FOCG]G;XV:U^S]\8O!7Q5\/PR7\WANZ_XG&EQ\'5_#/B/GQ!I@/8
MYP0>H(R.0,>W1R^OQ/X(83"9+)^TK\.0Y7"5I*I15-V3@[PE*=!IV:?O-.ZY
MD_$ECZ7#WC%F&*SJ*Y:'$.JFO=E"<G?FYE:44I]>96B]>I_9E_PIKX3?]$R\
M"\_]2GH!_+-A^?IVI#\&OA.<8^&W@4^X\*:&/Q.++M[=3U%</\%?VFO@[\??
M"]GX@^'?B_2-1,]J)+O1;V[MK/Q#I%QWTW5M)9B]C> YX)ZD=>M2?&7]I7X/
M? 7P[=Z_\2?&NCZ1Y=JTUMIUG=VMWK^HD'&W2M*W[[YCU! *\9)!P#_$:P?%
MD<>\H4>)5F/-R\BCBE-M2M\*DKQ5M7=QY=?:6]X_M;Z[PI++%F,I<-/+;73;
MP[:NKZ)MM2N]E%._2^A['H_A[2/#.G6^D>'M.M=$T^W7]W::/86EG:@=ML:K
MM[GISTSZ KY@_9 _:2UO]ISX:ZK\3;_P1)X+\/W/C'7]'\$6S:@U[JNL^&-'
MN3:6>O:B<J$>_(+!5./EY&3DE>/FF59U0Q^)HXJM%8BG4Y:RG/FFJG+%R4Y<
M\KR7,N9\TO>NKNQZ>79QD\\%AYX:,50</W24++ENTK)022[:+2W<_C[\>>*+
MSQGXU\7^-;N;[1?>+_$7BCQ1=#'0:OKW]L ?Y_(US%>B?%KP1=?#/XG?$3P%
M?0^4WA7Q9J'AZ&7L1I&IY\.D?A7G=?ZGY3_9M7+<E>6N+IN"=/DLHN#@G#DY
M?=Y>1Q<;)*W+8_S*S#ZVLPS'Z_=.^M[IWO\ :OK>_?J=#X/\-S>,/%?ACP?8
M?Z-?^*/$?A?PO:WG?_B<:]_PC?MR/QXS]:_M^^$/PV\,_"+X=>$OAQX3L8[+
M0O".C6&EV$8C +K9VJJ)\^K$%B0 0V1GY:_B!\*ZY?\ @_Q1X8\5:5_Q_P#A
M?Q'I_BBU(Y_XF&CZ\?$GO_//\J_M6_9^^-O@G]H;X::#\1O!VHP3V&HVRQ7U
MC*5^VZ1J"C_B:Z)JB-D*\9 !X'0/EN%7^7?I,X?.U'AAVG_8ZC4<N52Y%4YE
MR\_*FK\O,H<RM=M7YFC^E?HV8C)5B,_4G!9J^5)S<5+EUOR\S3UTORZV\CZ!
MHHH) ZD#ZU_)V^Q_7&G6UO.UO\@P/3_/^0/RHHHR!U.*-/(84444 )@=,#'I
MBEP!T %%&1ZT!IMIZ:?D4II]C!5 ^8\]N/?V.>G0\]".?Y[?^"RD>COX\^#D
ML/D?VZN@>,ED)_Z _P#:?ADMG &07+?K^'[:?%[XN^"?@KX(U7QQXYUJVT32
M]-MLYN)E-[=7GV8E=.TRUW;]7U>0H55(PS,Q'15D9?Y'OVE/CQJ_[1'Q:UGX
MAZO$;'39Q_8WA+1)<9TC0-'_ --TO37VJ%W:I?DLQ"@;B3ZU\SQ/B<+]0>&;
M7-)KK=V7G=^BUOOT/Y0^E9QODV6\%2X5<H3S3.&N6*Y9."C=MO635]E\+>_F
M>%T445^:^7R_0_S9H)R<8J[;44DKO5N*6BOU:/Z0_P#@CI)=3?L[^,8KH?N;
M?XKZV+8D=AH7A@X/X\8_^L*_7('+ ]B#Z]B>GIT%?!G_  3M^&-W\*/V7O >
MG:I9FVUWQ+)?>+M3@ZC=K+$Z9R,\C1%TA6SC!# X(K[T4':%]V_-C_+TK]>R
MJ@\/EF7TVGI"+=[[.\M4^R:^_J?[&>$>7XO+/#?@W XI/F7#]*34KJ2<ES).
M^J=IK>S5[C%EPXC=M^1GF/C\,=O3MZ$CI\;?M*_M:VO[/-YI6B1?"?XH?$C5
M-<TRYO[;_A!?#C:KIEFMJWV0_P!K:MN"V+$]V1L*>/O$#[&C01HR%2H/3?)G
M@9Z8&<=#GJ1BH9;6&>,>9'YX'>3&3[$XST[^@XKOKJZ:H:-IIR23U::O9O3?
M9Z)H^MSO"YEC<KEA<MS!91F,HM*HHK'634HMV=D[*5_E97L?R2^%_''QZ\+_
M +2+_M*P_!_XBRZY>^-=7\17.@1^"?&7V.ZT_P 1@?V_IBL?"I*NOA4!E;DJ
MP# Y (_?_P#9Q_;+M?C[XEG\*3?!CXO_  VUBWT$:[+<>.?##6'A\@+9_P#'
MIJV2))"=47LH(W 8%?:*V,(_>)# L)C.8/LRYQSU)YR/7.<^G(I(+.T@$T44
M:QRL%:7R< KC!('L<=.?TKR<!DV(RZ[>8N47)R<7'2[;;6ZV3>JOLNI^4^'_
M (8<1<!8K$2P_&[S?+<WS&IF>?4YY+%-U)-R:B^9N+;E:4HJ^B<D['0#UQ@G
M&?\ Z_TI: , #T&**]D_<=+>5OPM_D?GW^VU^QUX>_:<\'/>Z8MOH?Q0\+VS
M2^%=> 'E7.";Q_#>O!5R^A:E(0)5R2&8L"/NM^>7_!)/PQXA\%_'/]H;PGXF
MTZXT7Q%H'AKPII>M:9=\WEG?'5/$N22"05(/7W!K^@*41DJCN,'@1XZC&,GO
MZ^OT]<RWTRPMKNXO;>RLX;F<?Z1<1VQ%[+M& "1DX_ ] 2.,UY4\IPW]I+'V
M2DM[/39^FJ?7KUU5S\FS?PHR;,N/<@\0,#&.4YKE#ES*,4HYBFI+WHQ27-[S
M7,UJM7JKO3D6-@?D 1E((.,=-HZ_YZ5^%O[?_P#P3Z\2^*O$FK_&OX*:9_;6
MM:CFZ\:>"+?/VS6;\$XUS2F9F9I$7 ?020LC9=, E4_=?"!#W!Y^G;C^7;&.
M>*155OE4!O9AD8_''ZFM\?@,+F>&>&Q*>^C^TNS3]+75_+30^AX^X"R+Q$R-
MY'G\=TW&I&SG"33M)-J]D[-I22=NFC/X8]8T?5=!U"YTKQ)I6H:)K%N,W^CZ
MQ:_V5JMF>OUZ=/\ .339M;O)+;2M$FURYN;C_CUT?2[K7_\ 3/?_ (1[1>_(
M[8Z5_;%XF^&G@/QG;B+Q7X+\,>(T'&->T'2]57UQMO0P';IUZXJGX6^%/PW\
M& S>$? G@SP_(1M,^@>'-*TD8/\ UXJA(YY[?7K7S*X,L[+,)I=E=:=M&EL?
MRA1^A[BJ&8/ZMQU4IY2WK"&$J0;AS?"^2<$WR^[=MZGXQ?\ !/+]@?Q#H'BC
M2_CC\9M$N-(U/1_])\#>$-3.;VVO\#/C'Q#C'_$S93\B]OOL,;0W[HW5K#?V
M5U:/&LD4MJUO(.Q^5E]LCYNW XYK1$<:IM"[$/&%&,X[?_J/3IQ4D2Q@?(>/
M3'7)^I[D=O2OI\#@,+@,+]6P]W;JTFW=6DW>^^J26BVZMG]7<$< 9'P+P\^'
MLOO452$HUZD]9U>:#C-S<G*4KJ4K*4I**;W>I_'C^U7^SCXU_9R^)VNZ1K6E
M:A_P@^J:SJ%_X%\3_9@VEW5@1G:=O_,UKD?GGH:\1^'7CGQWX!\5V.O_  P\
M0:OH'BRW_P")?;3Z /\ 3=3_ .H 1_S-'M^=?VL:YX>T3Q+93:;KVFV&K6-R
M,7%I?VMO>6A'.0T<@ P.VY3R,\<UPOAGX._"KP3-->^#_ /@_P /7Y_Y>-(\
M,:'I5Q%QZV-DI/ .<G'7@X%?-U.%?]K]OA<P<;RNULXMN[2::O:[MJGL?S3F
MGT46^*WG?#W%,\FRZ=24W[/FC4R^4YN4G!QE%N5Y/E=T[J+EL?C9X'^"7[17
MQ3\!>)/C[^VMXIUS4?!7P[\$Z[XP\)_"?Q"#I&DWE[HN@WEX=<\;>'E RRH&
MVKD!<[B,<'\/[.&:\^S?8(;BY][.U&JCGKW^O'7UK^YR:UANK8VURB2)-_Q\
MV[8 (QCISQWQVP,>HPK/PGH.F[WMO#>DVA!P##80'(XR3C@''. ,'^?=B.&_
MKG+?,&W&VZUOLM6WVZ;+0^AXS^C10XBHY)1PW$4E+*%;/N(<_P#:9WGF>;6Y
M6Y-0A%\KBDDDDDD[7/P>_P"":?QL^(_PLNK7X.^)/@W\2+WP5XF\6&YT?Q98
M>$M4-KX6OO$C!B/$0/"Z*"ORR#!7W&:_0O\ ;0_:5D^$W@_5O >C?#7XC^._
M$WCWP7XAL=-N/"_A;4M6\/:4=5MCI _X2+5U(6P :Z#?=9B!@A237WS#:PVZ
M>9M@^JP^1Z]< CT_/'7DOFBMY "1&<]"8!-G\^F>@ZUZ&'P&(P^&^J_7VTKQ
M3<5HG>^EKWM)VOMTZ-?J^0< 9SPWP+_J;A>+9-N$J<<^>7IRC3FI1Y%"[2]V
M3BE;3IY?Q)_\*J^*?_1-/B1_X0GC+_YE:_33]@W]HWQ+^R[I'BCPIX[^!_QM
MU?0M>UBRUBTU/0/ >NZK>6H:T'RMI."P (!RK Y SN Q7]&OV&$@?NX3];.V
M_/K3_L=FIRUO!GCYO)5?3T!Z<=.GUKS<'PXL'BOK6&S"6[NN5=;W6KZW:[V\
M]3\LX4^C9B.#.(_]:,EXXD\S;DY7R.'+)3E><?CVFI23LDO>ON8/AOQ##XGT
M'2-?M;:_LK?6-,L-3MK/4[5K+5;9=5&Y1JFF;E$;X8,022"K[<@>95'QYX(T
M+XA^$M>\'^)K"+4- \1Z/?Z/JEE)TGL;M#&PSU7()/7((R01FNYBCC0_+U[<
M8XQCCV]!Q]*4J>G!]L$Y_3%?2VO=:---/2ZM:STMV;/Z<JX:.+P4L'F%IJ<.
M2?NIJ=X.,O==U>7-*UT[.2ML?R5?M+_L&_&C]G_6+N\TK0=<\=?#,W ;3/%N
M@VRZLVF:?QN'B'25)&CA2=N5)7=QGFO:OV!?V[O#_P"SOIVK_"OXK'4/^$$G
MU*ZU+P[KVF6IO;SPQ?GYM?TO5]+&2FC(X4I(-Q4%P%RP*_TMRVZM"8Y5AF&>
M!*N5'8YP/S'J:\VUOX+?"OQ:QE\3?#GP+K5T/^6^I^%M+OST[F_LY"#V!!'Z
M5\TL@>'Q4L?EN.<7[UX-*2=[WO:VCVU2?6Z:N?S9AOH]XKA7C&7&/A[Q3_9#
MJ.3EP_GL7CJ,G.4G+6+7N-MM)[1:L[JZ_%?]N;_@H-\//BQ\.-0^#'P3U+5_
M%-WXJ^SZ=XE\1KHVJ6.E3:+>;2--TO-@!K)\0G.G*%P "22Q(V_-_P"RA_P3
ML^)7QGUW2O%'Q/T34/A[\*;.Y^WW2ZO:G2_$/B@X &F:;I7 0#.1XN)#N WE
MJY4@?T?>&/@_\,/!Q+^&?A]X1\/.,_\ ('\.Z78G@_\ 3E&@Y'I^O;T\JJ+L
M2,"/@8' S]/4_3IZ5?\ 9'UO%+&9G[SBERI*RTM;1W]=%=W[;>IB/ K%<7<6
M87BSQ*XF><2P-G3X=R*#P.1)Q:<>93O+7E3DEK)WNTGIS7AS0=+\*Z/IV@Z#
M96UEIFDV5CINFV-N-GV2PLU%FH4')VHH"Y))(4DMN)!_$?\ X+"_!OXI_$"]
M^%'B[P#X#U_QKI?A?3?$]OXBFT"U&J'3591M)TG)W9(8 C X*]58U^[*#?\
M,CE_ZX[<?YXZX%,>(-Q(!Y?4$YY(Z_AZ]AC.<XK]#X2XCQ/!W$&7YY@(0J2P
M5W&$FXQDI1Y90;46XJ4+QORNR>VA^P<3<)X3B7AROP[/_A)PB4(PY(Q?(H)*
MGRQ5H^YRQ:MLUIW/Y+OV1OV^?B1^Q[<3>!_&7AO7/%GPVGN3<CP9JH_X1WQ3
MX/OV()70$UH@,IP/^*?R".<,">?V"TG_ (*Z?L@:I912W^O^.-&NCDW6E7G@
M75M3FM&]#_8JR$ >N2?]FOTIU7P;X7\0H\>O>&]$UE'X)U;1-,OO_0D(/8\@
M'WQQ7FMW^S1^S]<S>?>?!/X37DW_ #WO? OA<SGTY.BD_D1]*^XXDXQ\/N*\
M6\SS'@;,,IS.3YJDL@SU4XU)VM*<J<Z,DW*UY-*+DK*7-;3X7(.#?$'AC"_V
M;EG%^7YMEB345GV ;E&/2*:=[)625[:=.OY*_M#_ /!6SPMXA\-:EX"_9<\/
M^+/$7B_Q'9#2+3Q+?:.^E_V$VL*Z?\2#0&(U_6]9PRLL:HJI*N_+$@CXX_9/
M_P""8OQ<^-&N:5XE^+^E:K\-?A;'<_VC?QWX-EXW\4CC_B6:5X?.%\,')R->
M)#,,D XX_IG\+?"_X?\ @B+R?!_@7PKX>0GIH6@Z5I9'M^[LEXYYY/0]J[F>
M/+<0_*#S()/)].P&>!ST&<]3Q2POBI#A3)LQR?@G)ED[SAVJ\05)_P!H9_RN
M/*XJ<5",;IVTBHQ7-:+DVQXCPOQ/$V:Y=G'&6</-_P"R7>/#\$\#D2:=TU'5
MNUKK>^EW8YOPKX0T+P5X;TCPKX;L+?2/#_A_3;#1]'TVV4065EI^D@6EI:C'
M0 !1P,G ZGD_GS_P4%_88A_:G\.6OBKP1/I^E_%WPC;7%OHMU>8_LKQ1I[$F
M\\(>(L'G3Y2I(."0V>V=OZ:C.#Z<9_7_ #_7L4E3S GS[?P)[]AGV_3\OSO*
M.(,SR'.8YWEV*G_:BG[24G)MU&WS356[]]5+RYU)MWE=-22:_1\XX:RC/LF>
M0YAAHK+%%1A%62IM1:CR66BB^6UK:)=&?PB_$#X9_$3X4:W-X?\ B5X0\1^#
M=4MS]F%OX@T860U+M_Q3WB+_ )C7U[8]:XFSO+FSD_T"_N+;[1R/L=U_97H>
MOZ?_ %J_O*UCPGX9\1VYM=?T#1]8A(S]GU+3+:]'ID"[##MUQD]_?@-"_9^^
M"7AJ\.J^'OA1X T?42/^/K2_!^A6%[S_ +26:GZ$,/;G-?TGA_I*0EEZI9EP
MG2JXM12YVX2A*25KI5*<Y13:O:[WZ[K^;\1]'#%1Q;JY=Q34IP<GI%S@U!R;
MM[LHIVCIOK8_F:_8K_X)^_$']H/Q?I7C7XE:)K'A+X1:7=&_U._\0:<;+5O'
M> 2=,TJSUD9(_P"IO W'H 37]+GC_P <Z!\$?A=K7BS_ (1_7]1T+P7IMC';
M>'_!VCMK6K7%CE=)TO3M)TA2"QW?95VY P>I&%/LP6*). D9QC* X_+^6>O!
MSWJ;9E=DFTYQDD9&#SD@\9_R>]?A?&7'N9\>9O@<7F484\LRMM0X?HWI0C%M
M/XE%>])+6;C)6LE&RU_:.#O#[+N"LLQ^%P$I3S7-(OGX@G>I/FY;62E*3LG=
MI)J[:U/XW/VK]3^*G[27QX\:_%ZS^"'Q7\/6&MC1M/TO2[OP%XR&J6FGZ/H)
MT@MXA7_A%3@$DG )QTK/_9>OOBI^SS\>/ /Q>O\ X(_%C5['P?=7YUC3+/P'
MXR.JW>GZOH/B32-5;!\*XR#JP(SQQTK^REEC7]X;9<B/!00J2!SST_/OS2;4
M)\P6RF3RO]3Y2 D_D,<'KFOTK_B/$O\ 5O\ U67"M-95_9?^KZC_ &W5MR<O
M+>WL]];V^5S\[_X@6_\ 6/\ UG_UH?\ ::S'^T[_ -C*W->_\SUOUWZGSCIW
M[2'AK4?@>/C]_P (?\2[;PZFBMK!\)W'A#55^(I/]I?V3_9H\#X-^;_S!CRP
M_3YB3@U_,)^U]X@^)G[2?QZ\1?%72O@A\6-$T>_T_P ,:-I&F:I\/O&5O?&Q
MT@EF.K ^%2>3DXR<9Z\5_8:(F<!P9+<<DQ #G].HS[>U!AAE)9K=5/0,ZK^&
M1T]SG%?!\ \>X?@+.<=G.#X>CC<4TX1]ICYI0A.S<8I1DI-V2;=KI6LM;_><
M<\ XGCG)\#D^.S]QC&TI26 2NXK=V:L[+J]]3^,']G(_%7X$_'+X:_%N;X*?
M%S5[#P/XC%U=6%GX#\9?VM=V'B/0?$GAS5C_ ,BKU'_"0C/TQ7]6^A^.[7]H
M#]GW6O%6A>'_ !AX9/B[P5XHM;#0?&>B76A>(K.^_L_5M)Q=:22S<W@"G!VL
M5)./E ^@#;V[E2]O$X)ZK'@\=,\G)!/U]/2KZ*L8PG3 QQVZXQVQ6G''B,^/
M\SR[.*^2T\JS+*N1)QJ3:J0A4550DG%*UTU>\O=D]+.QGP+X<?ZC9?F>6+,I
M9IEV;1E%KELX.<)0YTDWJN:Z:UO%'\9'[/\ \=OC-^Q-\4KK5W\.Z[IEO<'^
MS/&W@'Q5:ZIX;LM8L,Y%WGOXIR,GQ<<JPR&!4E:_>CPK_P %<_V2M=\/_P!J
M:YXA\2^$]4CM1-)X8U#PYJU]JTW'(TI-%L=1&L^H*$@DME5[_I)JGAS0M?B^
MSZ_HVBZS%GC^U+'3=2[\?*UHR_F >E>7R?LS_LZW<WVN;X(?"FZG/2X/@3PO
MGUQQ8<CG]2,8R*]7B'C[@[B_$PQN?<*RPN9PA"+GD&90I^TY(QC:I"=*2E?E
MO>RDN9I/[)Y.1<!<7\*0G@^'N*+Y7*<YJ.>X%R<>:4I6@[W5N:R>B:2]3^7K
M]I_XE>,/V]_VD9]:^$/P^\6:Y8VVEZ?X3\*6%GHWVV]^P:1="\.O>( <GPNH
M/B'Q#MR<]NPK]Z/^">_['9_92^'-_=^)[BVU+XI>-OL%WXJN+3/]F:/9<KI7
MAC2<\?8--&0.I)/  Y;[LT+PCX5\,6B6GACPWI&@6PR(X=$TS3;" 8_V;-57
M_@14<9P375 .J."V7/.1Z$8P/;..G7.0*\[BGQ-QN=\.9?P;EN!>3\/8))*+
MG*=2IRJR=6;M&3O:3]UN4KN4DK(]+A7PQPN2<19AQAF>.6;Y]BV_>Y5%1O=M
M0OJM[*S22MN?$G[:7[)GA_\ :S^%Y\/7,L.B^-?#EU_;/@SQ&%RUGJ &1INJ
M*HW/HFOC$>JJ!N90" 6!!_E-^,?P#^+_ ,!/$$_A_P"*'@G6/#DMO=_Z!K/V
M7^U?"NO=/^1?\0'H3QP>?:O[D(@P!^8.#WXQW'7!)Y]N.AXK&U70-,UFW^RZ
MKIFGZA:_Q0WMJ+W./9@PSGN<GW].WPY\7L[X P_]G17]KY2VW*C-M.-WKR/W
MHI/[4''EO>47%MI\?B%X09-Q[B/[3O\ V3FO+9U$E>36EY<NK=NN_I;3^"B&
M\^QR>=I]_<6MSP/MEG=?V5_A^OOWK[&_9@_8J^,W[5GBNP\G2M=TCX=FZ \1
M_$?7[3538V>GL0 ?#_\ PDP8^)?% )&6(VJOS-A06']7UO\ L]? JPU+^VK'
MX/\ PVLM4_UGVRR\%:!!?'&>XL0W/0XQ@^]>N6>G6FG6\,%FB00P@ 0P#C'H
M>_?G/UY'3[[B+Z1.,S+"R609'2R?,)0<95FJ3DE*+BW%>R;NN9M.4K7LVMT_
MA>'OH[TLMQ2_M[/*F;9;%\T:?/42NFI)6Y[+6*Z/Y].)^&OPV\.?"[P5X<^'
MWA2P&G>&O"6CV6BZ/9C&(;:T1E ! )ZG)ST)P!@ DKTS& ,':/<=3[YQSQ17
M\YU,7B*]2=:;<IU)2G.3<FY3DW*<F[;RDY-^O:Q_1-'*<%1IPI0C!0IQ48JR
MT2227W)'X#_\%7OV--8U=H_VF/AOI5Q?3Z;8+;?%C1M'M@;\Z;I ^V:1XHM
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M)@>@_*OSC_X>Y?\ !-S_ *.\^%W_ 'UXA_\ E%1_P]M_X)N_]'>?"[\]>_\
ME#0!^CM%?F_%_P %;/\ @G#/-#!!^US\*WN;C_1HH/M6NC)Y_P"H'R>F3QZ
MU^B-M-;7D4%S#+YT5Q_I-L>F1CDCV!/MSG\0"_@>@HHK\L/VH_\ @KQ^Q?\
MLN75_H&O?$.Y^(7CO3_]&E\#_#?3#XBU:#4?E 75=6&- T=2N[+.Y^;!VE2
M #]3Z*\^^'_C.P^('@;P5X_TV">WL/&_A+PSXQM;:X&+RTT[Q+I2ZQ9AAST6
M["^F,X&" /0: "BBB@ HHHH 3 ZX&?7%&!TP,>F*6B@ HHHH , ]1FDP.F!C
MTQ2T4!;IT"@@'J ?K110 8 Z#%%%% !1@#H,444!9=E]R"BBB@ P!T %%%%
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MDDDDELDDDO1))+Y)!1110,*_./XJ_L4>$OCY^V_X3^/_ ,6_"VA^+_ WPC^
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MX7\$^!]+OM0%KH'@RTMK+3+/42R_VGM"$G^UR<EMQ#84%CA21^57_!:+X?\
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M VVA^-_A?\.?!_A>U/A3XG>#?$6E^.]8\.Z79:,6TD\'1,JO]O ^(B!GKN.
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M-O!7AZ%(/AC\$-'UC(\1KX=L]&SH#Z[XA1%#^(-H_=G$3%U.S]=* "OY%?\
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M''7P/"GA_P 'E%/!+?\ $L52 ?MC5:;_ %4_T_J:LU6F_P!5/]/ZF@#^2?\
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M*D!N"0!QPR_V3:7JEAK&GV.JZ?=17-G?VHN;6X S]JL3SNY'/4$_7IR<;5%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
.%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %( G # 2(  A$! Q$!_\0
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M#J1*""V!P0I&<]3GKC [_P M_P"WY\8_VC?C=X?_ &.]3^//[+EQ\!]!U/\
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M<&L:OK6C?VQKND:!H,MO)KVL-X8N,:!O$:&XNLR*SQC8/B7XY_MW^,?VFO\
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M$_81_;;D_;'T'XF6^O\ PYU7X5?$WX.^,5\$_$;P7>ZFFK6.GZPRW"*^EZS
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M%H(\R+0G#+YH<Y*K'D!@Q/ZA_!7]DW]G/X I<W?P?^"W@+X?:E?0D7VJ^']
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M#+"RS*:3><N_(DO]HX@CG]DKV2A/W&KVM:VUC\4?^"J/A_Q5KWQ<_P""</\
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M@.+WB\R>#_LNI%.[YY1>ZB[-IQNGW;2LK:K8_69G5 264;<9Y'!)X'L3V_\
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M:;;=DKQ;M:Z>G]*_Q-^*?@+X/^$-4\=_$KQ1I7A'PEX?;3AJNOZI)Y6G:?\
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M+;SP]X:6%?#(!NO$FOLP9[+4@Y5=(T?80NXH%DD(!6(E@#@$GV'2WMGM1#!
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M77=?>O\ , HHHIW7=?>O\P"BC(Z9Y]*"0.I ^M !11D>H_S_ /K'YT9'J/\
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M4?F* %HI,CU'YBC(]1^8H 6BDR/4?F*,CU'YB@!:*** "BBB@ HHHH ****
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M_P Y%?B1_P /I_ W_1"?&O\ X56A>_M_G'URO_#Z3P+_ -$)\;_^%3H?^/\
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M\7# X+BS#SJ3E",$XU(7E.48QNYPC;FE)*[:M=7MT_0N5Y@?N2,!G!5T('X
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M_A[P'2RJOQ9Q/2R>CGD5+"UI1JSI54X1DG&I3IS@TXRB_=FW:2=M4C]?.?\
M8)]=C<_YR/\ )&#)_P!@>^UN/0_J/\GC\>C_ ,%>O!9_YHKXTY_ZCNB=\^_N
M?S-5Y?\ @K_X+A/_ "1;Q8>__(TZ#_,CWSVZG-4\HQBWI-/UA\]Y(^'7TG/
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M"/"&;*+I<2052MATIVY.:5&G4E!OX;3C3E&2E%I33B?JUO']_P#'8W]!C_\
M4/?*[Q_>/_?#>_M_G'US^+'_  ^8\#_]$.\9_P#A3:'_ /'*B_X?.^!O^B'>
M,O\ PI]#_P#BZF\>Z^__ .T/S5_2V^CTE?\ XB+A7'I+V&>6:Z._]E6U5NKW
M/VLW?[?_ (X/;V]OY^IHW?[8_P"^/\!GM_/U-?B9_P /H?!/_1#/&O\ X4NA
M_P#Q=0_\/IO!/_1"_&?_ (5&A_XT>XOM1^Y__($?\3;_ $>6[+Q#PS>NV'SQ
MO3=V64MZ75[)VTO:ZO\ MMA?1/R:C"^B?DU?B'_P^M\#_P#1"?&?_A4:'_\
M%?YS],'_  ^M\#_]$)\:?^%1H?\ \5_G)]L<OUS"_P \/Z_[=,W]+[Z.T?B\
M4,)'UP^>+\\H1^WFX?WXQ_P$^_\ L_3O_7!N']^/_OD^_P#L_3]>G.W\//\
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M*?NI:^\DOM-'W6.@Q10.@S16Q^Y!1110 4444 %%%% !7X6?\'"O_)A^A?\
M9P_PQ_\ 3)X\K]TZ^$OV_?V,=/\ VYO@59_!C5/'>I_#JVM?'?A?QN_B'2=
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M ]"_L#_A5'Q./_"0'_BGSXL_XGG;C^P*^'Z_JT_XAL/!W_1WGCC_ ,-#H/\
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M7_+'SEV(^^O^'%/A[O\ M':_]1\/M((_37JE_P"'%WA__HX_Q#^'P]TG^OB
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M4K_4]9^/7BB_U#5+PZA?7]UX7TI[V\OP-WF&4ZPB\@'Y?8_-@$U\OA,QPO\
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M-F82+"&1OM=O^"/6AJRK_P +W\0?,2.?!&DYR "< :TV>N.2O./J*9_X) :
M)(U'QV\1&-T=]Q\#Z.) $)!'E_VX4/(X_? X[9XKRUB\-*_*DTXRLKO1:[>\
MM;+1-N]C]!S/PF^D)BL'/"+PHX12E1KY!=<09 FJ6>I^TKW5._-3NG=R;32L
MTD?AO5>?M^']:_=C_ASCHAY'QWU[_P (G2__ )<G_/U%5_\ AS5HG_1>-?\
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MZ>WX4M?1G^L04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !00#U
M/UHHI-)[I/U2?YI@%%&1G&1GT[T9 ZG%, HI-RDX##/ID9_+K1D#@D9/09ZT
MK+LM/):?AH)6=[6?>UGJN]KZKSV\@P/0?E00#U /U -+119:.RNK6=E=6VMI
MI;I:UNEAV_'?SOO?O?K?<3 /4 _A1@>@_*EHI_IMY>@K+71:[Z+7UTU^=Q,
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MZ#\*/^%U_$;UT_\ \%)_PKX?TV/WJUM-=--=]--?/37SN?:%!&01ZC%?%_\
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M!Q<(Q?-RN'-%)QM^I:_=7Z#^5+7Q?_PNOXC#OI__ (*6_P */^%U_$;UT_\
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M/XB:QXIU*^^'<UTL.GK^SO\ V3X4NK0V*WNF_%;QJS:YKGC2.7PW)XCT!O\
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M?O[5/[*D/QEM+O4M.,MMJL;&[L[RQM2VIV6IJ%VF5=B?VSHC @O;-EH\G:S
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ME=TU?F5U=>::9_.CKW_!.7XT^)-9T_0[[QSJ0\/:5_H5G:?\(WK/]I6&E?\
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MY1K'BS]E[3+.RO?^$;\%WDMK:>*5\/Z!:> HSJ5^-"UDZ+K6EZ-HA\/HV?\
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MTR[T.X^W:5IT'B#7E\-KJ1T2;0%UJ/PZVO?\(_+XB?PWJ<OAP:^\/G,K$;P
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M %%%% !@>E)@>@_(4N1G&1GT[T4 & .@ HI,CU'YTN1Z]>GO0 4444 %%%%
M"8'H/RHP/0?D*7(]11D>HYZ>]'K^(M-E;T5NF^B[==-.H44F1G&1D]!D9-+D
M>OO^'K1IY!==UH[=-'V]?+?R"BBB@84444 ! /4 _6BBB@6GE^ 48'H.>OO2
M;ESC<,^F1G\J7(]11;I^'_ '==UO;=;K=>J[;^04444 %%%% !1129'J/SH#
M3R[=/N# ]!^0I< ]1FC(]1ST]Z3(]1^=+3R\M@%HHHI@%%%% !1110 4444
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M:W\.>'? 7BJQTRT_9@TG5M4^*OC3QIJ/C?7M6_:M\:>(M!T*3^UO#_APQ/\
M\(C)I7F,6C8'PCY4LBF2.)EW_$O_  4P^/NA^(_AOX ;X)?#&\\2ZKXN^*?A
M7QGKU[X[B\&> _$.I?"OXU#X3R:+\+M<^(7B#PF3XA< >)"F?&$:Q_*BJ0"
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MN.<KXA.0,_\ %,KR.V?4<<?2OD;]M#7/BCJ'P'\56.IS:RINCI6\7%DNF?\
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M'&6<.<;+A:I#/6[0X9FJDN&XVDX*MRN<FW'DC.3NU)RZV1_0L.@^@I:^+_\
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M:;I&K6ZZ1X-\->&=1TS7M#U[&LG71CQ*WQ .OQZ'_P BJ?\ A"<1^(^#M0J
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M1\5XA8GB#,YYJHVC3@X)*"22248M0TLE9):*[=SR^#. N$N ,LEE7".40R;
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MU%)D>H_.EHM;I;\!W3ZI_/\ X(4444 %%%% !1@>@HHH 3 ]!^5+@'J,T44
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MT+%Y_P"#6+_XU7C/Q \=3^.M2M[WR;K3K"ULR;32S=J&8G&6;8%7<?90IZ$
M"@#Z'_X7]X0^U>1]CUOR,?\ 'W]B.S/^YGUX^]^%>L:1KFE^(+&'4]*O8+[3
M[D?*ZD']/7U4C'H?3\XJ]%^'_P 0)O U]/.8+G4M/N;0-=6OVM258<AE#!@&
M7G!QTZ\=0#[SHKYK_P"&A[+_ *%B\_\ !K%_\:H_X:'LO^A8O/\ P:Q?_&J
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MW(6$@W%1WR?M=_ >>UO;_4YO$FCZ>--37+N[\4^!]9TG3;HG2/#FNZ(-VMB
M2ZSXHT#6=%E\(0N2]PI9<Y1(7AU#]K_X,6>@Z[XATS3O%FN_8]'U+5[R32?
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MOIG_ 'R?_BJ/^%8^ ?\ H5],_P"^3_\ %5Z#10!Y]_PK'P#_ -"OIG_?)_\
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M )@>@XZ<48'H/RI:* "BBB@ HHHH 3 /4 _A2T44 )@>@_*EP/0444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ", D8# 2(  A$! Q$!_\0
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MSN_B/^RK\0_[+M_M.L^$%L/&]G;P<EO^$;N1+JN?3&A7%\3GOS@XXX\=4JK
MX]X?=1NK*[;BT].J^%Z^O>Q\#XD/,X<$\05\GNLTIY=[2+2;O_9S^O)62;^P
M]KZ::ZH^CO@C\=? GQ_\!:5X_P# >HC4]*OX1Y\!*K?:7? +OT[4[0$LDB$D
M, >FTJ><CW,L-@8\%L ^YX&/;/%?Q@_ #]HOXD_LX>+AXK^'^J_Z-.5;Q%X8
MU,E?#WB>Q&2K:HPP58'_ )G =B0=RE@?Z7OV9/VX?A'^TOIUK#HVI0^'/'_V
M8?VIX#\0:A;0ZO <'+:<H"KK"@#)ETXD9R6"X!/EY3GF&QB]C7:51:6>VG9.
M2W?2UT]KIV7YCX1^//#G&^&CDV<SCDW%-.U.4*DHPCGKA[G-@')QUDXOFB[:
MWY=['W:.@Q12*P(!!!R >#2U] ?T6FK)]+?U_5PHHR#T.:*!A129!Z$'\:6@
M HHHH **** "BBB@"$QY7&<'T^G;_/\ ]>F8$0.SG'H.3S^/3VZ_C4[]#_GN
M*\Z\8?$?P1X'BM)O%WC3POX0BNN+:3Q-KVD^'ENR.H4ZT\9)&"".O&#C(HMZ
M?-I?FT<N)Q.%P<7B<5*,4M.:4HQBK[OFDXK\5_EZ'\F.G/IS4)C0?\LF_P _
MA_\ 6]Z\23]H[X"O_P UG^%"=02/B+X/_P#ES^0Z?I7M$%Q!<1[X)!(!Z<YZ
MXY!Q^>*+K:\7Z2BW\[2=OG8QPN9Y?CG; YE1J2=[PIU:=1Z;^[&I)JVSTZ%_
MI1132Z@$YZ>QH.^Z75;>7;_@$&Z/V_[]K1NC]O\ OVM>+:C\?_@OI>H7>E:O
M\6/AUI>I:?<_9KK3-3\;:!8:I9WX_P"76\LVU!65NAVGZ8..*_\ PTA\!_\
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MVDG+:BV8_$Y/1F4+*0 OF  8_:SX)_ME_ /X_16R>!O&^F)KEP/.;P=KTO\
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M"G.HHRBYP;]V,DFTKZ<C5O0_8> YAB/JB]?I3T^Z/Q_F:CA&V*.,]1& ?7@
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M@&OS*_:V_95\8_LN>.AI&H1W&K>!=;O_ +3X*\7?9<FZL>,Z!XBR 3K@/0@
M,I##Y2*_5S]GJ42?\%5_VF$]? &I@>N6U3P$!CMQG/4_45^FGQH^#'@SXX>
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MQ_\ P3DT31/$?[9?P>TSQ#IUIJ]AGQM<^1?6POK.'4-(\'^(]7\/W8R",X/
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M]%IHV7:CE_U;_P"Z:D^O^34<O^J?_=-:O5/S3_)GK3^"?^"7_I$C\,_V=]1
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M(O-0V>#YM9U>[TBWN1!9Z]H_]HJ/$6F-P06.A^H/RX&#BOT/@+AS&Y^LOR?
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M@:KH+8[\'4E^EKC)RHK^;WXQ237GQ?\ BO--C[5<?$7Q_P#:B/;71R.>>/\
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M^3X?@O\ ]>_CC_U6/B.MG_@JE_R>U\2?^Q2^&G_J(O6/_P $Q/\ D^+X+?\
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MY\3^%<9)4_,O?J*_+#_EIY'_ "]?_6Q]?UZ?E7]I_P"S!^TW\/\ ]JSX=_\
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M_P""/MGX/UOXV?$?PMXKT32=;_M3P"-7TRSU_1M!O?\ 1]*UW2%W<JX)0L&
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M^%'B[P#X#U_QKI?A?3?$]OXBFT"U&J'3591M)TG)W9(8 C X*]58U^[*#?\
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MT2227W)'X#_\%7OV--8U=H_VF/AOI5Q?3Z;8+;?%C1M'M@;\Z;I ^V:1XHM
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M)@>@_*OSC_X>Y?\ !-S_ *.\^%W_ 'UXA_\ E%1_P]M_X)N_]'>?"[\]>_\
ME#0!^CM%?F_%_P %;/\ @G#/-#!!^US\*WN;C_1HH/M6NC)Y_P"H'R>F3QZ
MU^B-M-;7D4%S#+YT5Q_I-L>F1CDCV!/MSG\0"_@>@HHK\L/VH_\ @KQ^Q?\
MLN75_H&O?$.Y^(7CO3_]&E\#_#?3#XBU:#4?E 75=6&- T=2N[+.Y^;!VE2
M #]3Z*\^^'_C.P^('@;P5X_TV">WL/&_A+PSXQM;:X&+RTT[Q+I2ZQ9AAST6
M["^F,X&" /0: "BBB@ HHHH 3 ZX&?7%&!TP,>F*6B@ HHHH , ]1FDP.F!C
MTQ2T4!;IT"@@'J ?K110 8 Z#%%%% !1@#H,444!9=E]R"BBB@ P!T %%%%
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MDDDDELDDDO1))+Y)!1110,*_./XJ_L4>$OCY^V_X3^/_ ,6_"VA^+_ WPC^
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MX7\$^!]+OM0%KH'@RTMK+3+/42R_VGM"$G^UR<EMQ#84%CA21^57_!:+X?\
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M VVA^-_A?\.?!_A>U/A3XG>#?$6E^.]8\.Z79:,6TD\'1,JO]O ^(B!GKN.
M/Q7^,G[$'_!1#XA_\%%?#?[=7ASX(?"W1;;P?XO^'^L:#X$U3XNZ$=5O-'\"
MZ#_PC8_M;5@H UKQ$+S51NZ ##L6!H _J2HKA/!&L>*?$'ANPU3Q?X/N/ 6O
M7$/^E>&+C6=+\1'3C@8 U?1<(Y/.2"-O -=W0!_(Y_P5S\;6?P0_X*U?LD?&
MGXB:=+J'PRT/PC\.+_6(+RU&J65WX7T?QYX\T?Q!:X((RO\ PD/]O\J1D8(/
M-?TUZ'\-_@#XLT32_$/ASX;_  GUGP]KEMI^KZ-JFD^#/!UY8ZG8:N UIJB'
M^Q"I4J<@@G&&5B"K*GR)_P %'_\ @GEX-_;Y^%6F>'I=4M_!7Q1\$7.HW_P\
M\<?9#?6EFVL!5U_0]7M"3OT3Q&@(?EGR%VC!-?A9\$_V>O\ @O+^Q@9OA1\%
MK72O$G@&"X/]BV^I:[X-\8^"--!QD:2/%'/A@9QD$=0,C.* /Z7_ !C<?L]_
M!O6?AM'JW@WP+X=\1_$GQWI'@CX<V^@^"-"BUR[\0:M="Y!TM=(LO,LQH&T^
M(-5\0#Y--"L^_>P)^IZ_(O\ 8P_8_P#VC;/XBV_[4_[?'Q/@^*W[0Z:/?:1\
M-O!7AZ%(/AC\$-'UC(\1KX=L]&SH#Z[XA1%#^(-H_=G$3%U.S]=* "OY%?\
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M''7P/"GA_P 'E%/!+?\ $L52 ?MC5:;_ %4_T_J:LU6F_P!5/]/ZF@#^2?\
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M*D!N"0!QPR_V3:7JEAK&GV.JZ?=17-G?VHN;6X S]JL3SNY'/4$_7IR<;5%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
.%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !S )4# 2(  A$! Q$!_\0
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MP%\/?%7[.GQ2O]'UBV\/>%=*E\4>'?"?A_QI;^&;:TU;4M4:V;SXK"6]FEN
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MBLSO4HN#P52E6P2HXC#K$5\-"K5HSGAJ#J.C3:J4I4]*=:E*DG%5:BE^@_\
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M_P $[-*^!GQJO?@O^U]IW[3'CKX$_&V*YN)Y/"OB_P"./[-7@CQI;>*?A_\
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FO_3<#]6X&2658BR2_P!NGLK?\N:(4445[Y]H%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !! IP# 2(  A$! Q$!_\0
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M&$(*FO:8BG3C32C""AS4HQY$N6,7&3CK%)NZO^//_$/=_P $N/\ HDGQ<_\
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ME=*ZO^+'_$/=_P $N/\ HDGQ<_\ $L/VIO\ Y\%'_$/=_P $N/\ HDGQ<_\
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MW9VL_DV2\YSR*C*699E&,[N$I8BNHS2=FX2<%&:3T;C*23T;3T/Q1_XA[O\
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MP_\ "JI_D?BC_P 0]W_!+C_HDGQ<_P#$L/VIO_GP4?\ $/=_P2X_Z))\7/\
MQ+#]J;_Y\%?M=11]9Q'_ #_J_P#@;#^W,Y_Z&N8?^%53_(_%'_B'N_X)<?\
M1)/BY_XEA^U-_P#/@H_XA[O^"7'_ $23XN?^)8?M3?\ SX*_:ZBCZSB/^?\
M5_\  V']N9S_ -#7,/\ PJJ?Y'XH_P#$/=_P2X_Z))\7/_$L/VIO_GP4?\0]
MW_!+C_HDGQ<_\2P_:F_^?!7[744?6<1_S_J_^!L/[<SG_H:YA_X55/\ (_%'
M_B'N_P""7'_1)/BY_P")8?M3?_/@H_XA[O\ @EQ_T23XN?\ B6'[4W_SX*_:
MZBCZSB/^?]7_ ,#8?VYG/_0US#_PJJ?Y'XH_\0]W_!+C_HDGQ<_\2P_:F_\
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MQCXJAU#6OA7XNT_P9J_P]^%U[\5OAS\:=+TWP5X.TQ?@=X'\2_&G0_"'[/\
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MIMK;:=#)>-,T=C;P6B%;>*.-?F;XP?LP7WQ(U3PQJ/@CX^_&#X"6GA?0-/\
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MM/\ #7Q):[\9^+="\,:;KK><:M\#- _9O_:9\#? /X2>+OV2OANOP)_X)X^
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M_P"/OV;O!'P%\=_#?]GWP9I?BSQ7!X,U7]GNX_X*"#2OV@=1U"?0K&YU31O
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M%*3>(=2@Y*3:3P\7RIN[_F7\4_M&_#NTU7]N6Y\6?MO_ +6'@[]K[PI^U?\
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M;2)/AKH^B>$] O==\26]S)ITDNDZ_/>Z.FDV>G:E=ZG#J=U/IFE7/U5\3OV
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MQX^EU?0O$EW\0?@+\5OBA#\8?@_HUC#:6?P-UCP-XH^'L=SI6E?"Q-$\*Q>
M]8U2SO\ 2[O4](T'7M.^X/V3_P!GW4O@I^S+H'P'^)3^%?&,UM>_%E?$<6GP
M7&I>%=:T7XC?$SQUXO32I[37+"TDO;:30?%<&EZQ:7MA]FGG6]@47%FR2R\%
M\//^"=W[//P[U>SU"&Z^,'C+2_"W@WQ1\._A-X2^(OQI^(WC'PM\!O OC/0C
MX5\1^'?@G9:CKHOO S7?A/9X2L/$D.I7OC/P[X33_A%_#/B31M!FN=.G?M(*
M53LYS>D4U.+BXQ5W9QY9-35K7MWL:?6\)"KCKN\:F*Q%2/)AZ=6.)HU*,Z5&
MFIR4705&O*.*BTH*3@DK5%%'Q=\-)+K]F/\ ;S\9V7QD^(W[:'@WX.6?PF\8
M:=^SUIOQ?^-WQ!_:&^&?[1NJ^$?#=C\3/C/\1W5O%/CS5O#_ (V\!>%;&[TG
MX<?">[T#0O$FK>'_  [\1_'ENGB>:^TO2?"6I^U!^UM>?&SXL?LN_!?X"WO[
M2.O?#KXQ^!_V@_B5JUK^SMI\WP=^+_Q*U;X(^(/A+X6M/ ;_ !$^+=W\+YO@
MM\.-,E^)6H^*O'/C>/6/#>NZ]>:7X+\'^%=9DC\1:G8ZG]M_"K]ASX5_"_XD
M>'OBM>>-_CU\7O%W@32]>T7X63?'CXT^-/BQ8_"?3?%-G#IGB,>!+'Q+>RQV
M^LZUH]O#H5_XOUYM?\:RZ%]IT8>(TTW4=4MKWTWXZ?LW^ /CZ/!^H^(]0\;>
M#?''PZO]6U'X=_%+X6^+M3\!_$GP1+XAL8]+\2VFB^(]+9DN=#\3Z;#;V?B3
MPQKUCK/AG6OL6EWFH://J6BZ->Z>W4I\\9-.34.7FM9*2C)*7);F=FU)MN]^
M;ET4;.6-P3Q5&M.,ZLH89476]G[.E&JJ5:$*RPWLW6G)3E"K4DZCG[257V*Y
M(T%3_,/PA\0G_:&\=?LX_LB>!?BO^U1\'_ VGZ9^UQXC_:$M_&OQ*U*W_:K/
MQ#_9Z\:?!+0+3X!:W\:;+7O$NO6VAV;?'^P\?S^+/ 7C35;[Q;X#TSP%;Z+X
MWD\-ZMKBWU;PSX#\2^+?%7[2VA?'7]LS]I30_@+_ ,$Z?%?Q.\,7GBOPI\5O
M%OPV\4_$+P/X]^"/[.?[2'AW7_C)\3/A[K.@:MXK\0?LV^']6^(7@5+B\T^X
MOO%>@^(M+U_Q3<3^*;&]O]:^XKG_ ()[_L\M\/\ PQX,T?\ X69X5\4>#O'?
MBSXI^'_CMX8^*'B[3?VA8/B?\0;::P^(OCO4?BRU_<:]XAU3X@Z7.^C^,-)\
M1C5O"6KZ+!I.COX<CTWPYX9M='ZF+]B'X 1_ 'Q!^S9-HWB?4/AOXX\60>./
MBC/JWC;Q+JWC;XP>*9O%VC^-/$^K?%3QWJ%_<>*/&<OC[4M$M-+\<0ZCJ/V7
M6_"#2^"$@M/"2VVC6XZM/[+DKM+X(MJ\VYU%)IW<H-PC%JZTO:UW4L?A(W5*
M=6$93C&SPM"56GS8B53$XR%:I"7-5K8><L/2I3CS4_W?/RJGSR^8/V#_ (KV
MWPC^$/PA\$_M!_$GXVZA\9?VH]=U[XV_#[P/\6W^+/Q?\3_#CX=_%7Q'=R?"
M/X0ZY\3KKP[K-GI^H>!_ UIX>TKQ6GC#Q'9SQ>-V\5:A(UOIU[:!?!)O^"J'
M[.?BS]HWPGX]U[]I_P '>#OV>O#/QAO_ -FWX6?#[PW\4/ VF^(?BY\4]6M/
M$VE>-/VAOCKHNH^)](U?PU^SA\/KGPWJG@;X56=_;O%XF\4W.H?%;5;"_P!&
MN?A3=VO[I=*\-^*/[.7PC^,-[\,-0\:^%K>XNOA%\5=!^,O@Z33672MGC?PW
MHOB30-,GU<6<<?\ ;.E+I_BO5Q<:/?>997,[6UQ+&TEK"5A5*;E*4X2]Z^L7
M'W;\WPQ<4EIR1ONDI2WDVN>GC,%/$5ZV*PU9/$*HI.C4HM4N=5OX-.>'C&/N
M+#45+6<(QKU4_:5I.'Y2>.O^"I/[.NN?M$:?KNK_ +3W@[P1^SE\#OC;X?\
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MSYY49PG"4(-U'*%.$Y59UN9V;Y:=*,*<$HJ\[%%%%9G"%%%% !1110 4444
M%%%% !1110 5B^);K[#X=U^],9F^QZ+JMUY*SSVK2_9[&>7RQ=6S)<VQ?9M$
M]NZ3PD^9$RR*I&U5/4+&WU.POM-NPS6NH6=S8W*HYC=K>[A>WF"2+\R,8Y&"
MNO*G##D4#5DTWLFF_1--_A<_%KX _M9_M->/M+_95^!W[-7PG^#^FQ^,/^"=
M/P/_ &K=3\6_'CXM_&'QI!X-N/&>KS^&+?X=RZK+:>)?B-\2KR]2S\VV\9^)
MO$=MJD4>FZKJGB&ZUC4+G3].OO'?B+\;_C5^V+\2?^"?6N2V_@_X=?!W7_!/
M[6?Q"^+_ ,+KKXA_&W3[F'XH_LI?$CP3\./B+=VOBKX-ZYX%O/'&B>%)+CQ!
M=?!Z+6+>TTG69-2O=:\6^&/MR:!:Z5^O?P=_9)^#/P*UKP-K_P /M,UZSU+X
M=?LY^ ?V6/#+ZGXDU35XH/A%\-=3OM7\+:==PWDKQWVMP7NH7+WGB&X#:E?1
ME(IY"B 53^'O['7P0^&&J?"C5_"FD:]%>?!>']H.W\#?VAXEU74H+>+]IWQW
MIWQ&^+*:I;W4KQ:N-2\3Z7:3Z.+U9!H-DLEAIXCMI70]/M:2E*486=I<KMK>
M2JIMMR>OO4[.VEI-=;^ZLPP%.K5JT<,HR4:WL:CI.51SKPS"-2524Z\ES)U<
M(Z4U!.DX5)1N^;G^1?!O[<W[0,7A/]G;]H[XK?"+X5>'OV5?VI_$WPT\/^!;
M7PIXX\3:U\=?ACI?QSM4N/@CXM^(VGW?AZW\#^*(?$\]YX=TSQOX:\%ZE!?_
M  \OO%5O-9:IX[TW0-8OF^;O WC;]IG]KWQ5J6L^'[GQ-XEU>V^&'PH^-OB7
MPC8?M5_%;]ECX?\ PJ\'_'S3-<\:?"#X,_#2T^"7A*]UGXG?%:U^'6GV.N?$
MKXI_&/5[SP3#XMUFUTOPSHG_  CTD^D^$_T-^'W_  3V_9[^&_C'PEXCT:3X
MH:KX5^&>OWOBOX._!3Q7\4_&'B7X$?!?Q1?6>K:<=<^&?PNU34)M"T2YTG3O
M$&O:?X/L[T:KI'P]L-7O+/X?:;X6MA;16_R?K7[ 'Q=\"Z_!9?"F>R\3^#M-
M\-Z7\./"^LZ7^T[\8?V6_'K?!?0-2U[4?!'P.^-3_#_X<_%/1OC%X)^%D?B+
M5_#WPY\>:4OP^^*WA[P5?2^&EU.]N[C5_$FL5&5&[Y>6+L[.46E;FT5G*3YE
M'234H\[LUHFGI2KY9S5?8*C0J.,O9U*U&4*:@ZKE3IN$Z]5RK4J5H5ZL:U%8
MBIRU8KDISIU/-?V?/^"@_P ;;;X(_"?2;WPW'\3?BQ^T1;?LXW7[.%M\3/%M
MGI;^&X_VAHOC6EYX3^/?Q!\*^$X[?Q'_ ,*03]GGXD:M<>-O"_@^+7_BCHL_
MA#P]'IC^,;O5O%-Y['XI_;Q_:9^!WQ"^+'PB^-_P4^#_ (F\<>$OA?\ LX>(
M_A5>_"/XA^);#P[\6/'_ .U'^T;K7[-_P]\/:VGC7PZVH_"S0='\8VVE_P#"
M6:K=?\)F\.D?VCKVBG59Q'X;@[:[_P""<G@3P-^S-KGPD^$G@3PAXG\0ZE+\
M)I=(\+_&;XK_ !GF\&?#_1?A-XBE\2>"_AY\&_B=X4G7XJ_!SP]\*=0UKQ9>
M_!;Q/X6M+KQ)X1UO6I];U*#6;B\O8'XCX!?\$V+>X\3_ +1GC3]I[PSX?O+7
MX_?#'X8?"&\\!Z?\>?CA^T#XGDT7X9>*/%'CFP\?^,?VB/BM;>#_ (AW_P 0
MX/%/B#29? 0\'Z-X3L/A1;>"=!U+PKJ$WB*]N]1M!RP[YY65KNT;6DWS1MRI
M27*E'F35K2:;YH\RM4JN33>)KNG2]G[2I:ER..(J2=?#NE*C&&(A[*G&A[:%
M2'+*%64:E7VM*56FJ?!_MA?M(_M*^$?V?/VRO@/\=M$\ ^#OBM=_L'_'O]H3
MX0?%;]G+QGXUBT632/A_#H_A#QMHM[#XFL]%\9>#O&_@G7O'?@74M#\0Z9J-
M]IOBO3->FN;(>'=3\.WUA/ZO\6?VD?VI?'6B_M=:=^SO\.OA3?\ PZ_9;T;Q
M1\,/'.K_ ! ^(?B[PK\4/B3\2]-^"6@?$KQ59?"J70?#NHZ#X)MO#&E>./#N
MG:%XJ\:W=XOB?Q>FI1-9^%O#UC:>+-1]WLO^">GP&D\(?&/PQXVU?XP?%W5O
MCK\+]0^"?CKXD?%WXL>*O'/Q,B^$5^M^S?#SPGXHU"X0>"_#D=YJE]JTT7AF
MQTV]UG7)8M;\27NMZI8Z?=6D_P 6/^"??P&^+_BCQWXCUC5?C'X2L_B_H=MX
M>^.?@SX9?&/QU\/? OQTTZR\+Q>"K.3XH>'/#6J6<.K:I'X0MK/PK?:YI$VA
MZUX@\,Z?IGASQ/?ZWH6EZ=IUK*G15DX[-2OR/EO[G-:'.I*ZBU%.=HR]ZUG:
M.$<5EBY8NG'W*D:G/]4FZ$IVPRJRAA_K<:L%4ITIPI1E7E&C5O6<+5>6G^37
MP'USX\^+OB[^S3XR\<>/_A[J_P )/@!_P2E_9-_:0T<?$_XQ?'+X=+;:[XK\
M*>/;;Q7\0OB)XA\.^(I/!.J:_KGB;P!;6_C7Q5\2= \=Z/H_P\M8KJST2YU>
M[\3C5_:8_P#@K+\2/#WA3]J4Z[X.^#_Q)\8?!G]D3Q9^UE\.]2^%J?&_PIX$
M\4VOA'5H- U/X=Z\_P 8O /A/6+N>;4M6\.76@^/?!S:MH6N:9J=Z][I7AJX
MTVVBU?\ 1^W_ &%OV;T\-ZIX.U#P?J&N^%=<_93\#_L7:UH&M>(]:NK#5/@'
M\/E\5IX>\/7/E7=O<QZTJ>,]=6\\4VEQ;:[<&6UE6\BFL;:2/S6?_@FG\ =:
M_P"%B7'C_P 6?'[XL:U\4/@3XE_9L\4>(_B?\;?&/BO6D^#WBG7=,\17WAG1
M'FN+>PT&YBU32;:>+Q!IFGV_B&\9I9=:U/5;ADGCIU:$G><6TN512C;3F<I:
MJ2WNU+36ZL[VMM+'Y57G*6)H.4(>RC2A'#\EHK$RKU7S4Z\;.HJE554TN=27
M*^9+V?SA\5?B!^W''^U3^PII-EX8^#NF?%OXB?!_]MN]U_P7%\3_ (@/\"O!
M/AS3-7_9:U'P[KWC5[?0;'Q!\4_&/A2WO;CPM9PZ-X<T&VGUGQ5?ZCIFI^'=
M _M1[CW(?MXZ_P##[X#?M4>-/C;\,-/B^,O[(/CK1_A;XX\"?#3Q/)JG@[XB
M^-/'GAWX:>)/@]>> _%GB/3=,N]#\/?$6S^,'@&#5/\ A*],%_\ #S4;K7[;
M5%URQT.WU;6?>_C[^QW\)OVBO%OPL^(?B_4OB5X5^(WP1TGQ_I7PG\?_  M^
M(_B;X=>*O!'_  LV'PI:>+[[3[[P_=P6^HW&I:;X/TW29+37[35]%ETRYU2T
MN]*NEO28^4T?]@+]G?2_"=YX%OK/X@>+/"?BC3/BM9_%?1/&GQ.\:^);3X\Z
MQ\9K3PI8^,O&OQQ_M#5GD^(OCFUL?!NB6'@CQ-JLBWWPVTV%M+\ ?\(WID=I
M9VL<])QCS1U5KJ,6GI4E)I2YVG%P:BE:ZEJY:7.5XG+JM'#JM22E35-5(4</
M.G*T<97K5(QK_67&5*IAJD:$(2I^TIU;U)56HW?EGCW]I+]L/X ^$8+SXT_"
MG]G?Q/XN^*/CWX3_  B^ 5G\*?B5\0]/\/S_ !9^+/B=O#T7AOXGWGC'X?O?
MZ;X,\&Z<L_B_4OB'X>MKK4O$.F:7J.BZ9\.=.UV;2(-1\C^-'[?G[27[-.A?
M&/P-\4?@[\(?&W[0O@GP?\!/B9\+K3X:>-?%FD_"WXJ^#?C-^T;X9_9WU+1M
M6O/%FA3>(_AQXO\ !GB/78I)I;D>*-"UK3M6T36K"XWVWB+0-)^H+'_@G[\%
M9?"WC7PEXZ\8_M"?&"Q\86_A2UL]0^+7[0/Q.\8:]\/D\!>(8/%W@2_^&&M/
MKUE?>!_%7@_Q9:6'B31_B#I4@^(LFKZ;IMSJOBW4EL+6.)=/_P""?/P%'ACQ
MUH?B[4OBQ\4O$'Q*U/X2WWC3XG_%'XH>)?&'Q0U:P^!GQ#T_XI?"WPI:^*;J
M:%?#_@KPMXSL'U:+PIX9T_1M&U&ZU77KW5[6_P!3US4[^Y%*@MXJ6NMH2C?6
M-K?O'RI)24HZN3=TX]*A7RJ+3JT854JB<U3PM:BJB4J+@Z=\;-T:4*<:U.O1
M?-/$3J1G"I2Y4X^##]I+_@H+)\?]4_9/3X4?LE)\45^$%C^T/IOQ2/Q%^*\O
MPHM?A]>^+=1\ K\/]2\)?\(9!X]N_B*OBG3VN(_$=I>VO@^;PLTNJ2VEKKD,
M7A>\^T/V2_CZ/VH/V>/AK\<)/"\G@G4/&>FZK%K_ (2?5(]<B\.^*O"WB+6/
M!WB[2;#7([6Q76])L_$_A_5HM&UHZ?ITFK:2MGJ$NG:?+<O9P=JGP7\")\;Y
M?VA5M-1_X67-\*K7X,O?G5;PZ4? UGXMO?&T%H-%W_8!J UZ_N9FU01_:VMF
M6T+^2BK2_!+X,>!?V?/AIH/PF^&UIJ-CX-\-W?B2]TNVU75;S6K^.?Q7XHUK
MQAK#3:E?O)=3K+K>OZC+ DCE;:W>*VB BA0")RIN*2@HR]S5)I-VDJGVI:7Y
M'%6T][O8X\17PE6A%4\/3HUTL.W*E3G",I<E=8M/FKU5R.7U65&*BE%JJXM*
M4D_E+]EG]NC3?CM\6OVN/@WXX\-V?PT\3?LV_%_XA>'O#.H76IO_ &#\3_@S
MX*U6#P[=?%#2M0U*.SCAN?"WBR/4O"WQ)TN$W%IX2O&\,:A<WJV7C#24KQGX
M+_\ !2"\^/GA+Q5X]T_3O#_P9\)6O_!0#X:_LM_"R^\>>%/&GC74OC#\*_'7
MACX3>+O"GBZ'1?#E]X>N_A_XA^-6A_$*;6/AMK'B W_A_P *>'-0\)ZWXSTB
M[DNK_38KUY_P3#T'Q_H_Q TWXH>/]7TR[\3_ +7WQ[^.-IJ_PNNI]%U+7_@)
M^T'?:+%\4OV9O'EUJ=K+)=^!OBUX9T2QT+XEVVCFUFEETO0-9\/:II^KZ+8W
ML._X@_84\<:GXA\;:IIWC'P78:=XB_X*0_L_?MGZ3IXT_5XQI?PZ^#?PS^!W
M@._\!-'!"((_$U[-\*M2FT66V4:%:Z?J&EP3-&\$ZIH_J]Y6Z\EKWM&RM*U]
M^=ZZ_#9I;Q:[VLFYJKC))R6&45)5'3HNG34:[I.2DJOUFHU-J<;4%&I"-W*G
M*/"S_P#!7+PA#\&/B5\8O^&6OVJ_LWPX_:3M/V=KC0I/A+XM@DUJ[O/C^OP+
M3Q#8:M+H0LH[ZUN-VIZGX-EC.LZ;XCN-)^'MU.FO:Q97#?4WC']O'X'>!7TV
MUU[1OC=+K \$:)\2O'?AWP[\ OBWXQ\0_!3P%X@;51I?B7XXZ1X1\)ZW=?#"
M"Z30=?N(-*\1+!XAN['0-<U*PT>[T[2+^[M_FKQ%^Q)^T1J'PO\ VIO@=I7C
M'X+1^!_B'^T7?_M7_!#Q9J-MXZ;Q5#\1K[]I?PG^U(O@#XL>';6!=(MO!%KX
MKT#4/!;^*O!_B"^UZ\\-:A9:POANQU73Y[+4?/OBK_P3X^/'CKXL^*OV@(K#
M]G?Q!\0?CCX0\"Z;\8/!7B?XI?M1^$O _@#QM\/-*U#PIHOBGX::]\)M5\'Z
MI\1/#>I>#YM&LO$'@GQYX8\*7\^LZ%+J>B^-]!M-?OM+M7RX=O=15Y;3DVTX
MTW%.\?=M^]N]7S)1>C3*]CDM27QQHQYJC7+BZLG.,J6"E1A)U,/:ERN6.<I>
M\U6IPH3O&<9/Z?U[]N?PKX*^.?Q3TGQ3K&AW_P !/#7[.'[)WQ8^'GB;P/H?
MB'QSXP^(7C?]IWXM_&GX:>$_#'A#3_"3:Y<>.7\<W7@SP#I_PZT7PMH$^IZK
MJ^OW4GVN\LKJ#[#E^/\ _@I%X+\#Z]^SUHL7[/7[6>M2?'KXA>._AZUF?V>/
MBCH7BCP3J/@7X:^(_B/<2W_A'6_#%KJOB%]5LM$@_LZ/P^US9S:%+KOBB+4Y
MK/PCK=K'P?C;_@GYJ\8^(=AX \,?LY>(/ .L?LG_ +(O[-O@OX+_ !*T3X@V
M?PUTR+]FOXD_%WQE=O#+X>UC4O%7@^UAT[X@>'Q\*/$>EZQXE\3_  _\2>'8
MM:N$UF:SLY9>-\)?L0_M9^"M!^&/C/2OB)\,-8^)7P;_ &F==^-'PL^#OCSX
MB?';XC_!_P  _#KQ9^S=XA_9Y\2?"K2/C5X[B\1?&[44FU'Q3K?QCTW4=8T&
MYT?2/$%_<^!-&\-Z3X8>#4[1*-!I-M7LE9R<;ODDDWRQ=GS<KDW[O1:73F%+
M*)1A*52#:C&GR3KSH\\GA\1&$I*C1J.G)5_8SQ%63E2N[4URJ49?8-_^W=\
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M4L6FPW#VERL?P)X-_9 _:0U;]EWQ]^P]X[\-?LP_"3]GOQG\"/B;\)[7Q/\
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M8?TO5-0U_3HM-U>:+QUJ5G^R#\2_@)I=GX3L[80S0K+XK\7Z=JWV>^DM99-
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MM_V@?'_B?XL^._AU=>&]*$O@WQ39OXV\8^)M.\/_ !.N==L-;\/^$]5LDN?
M_B/7] BU?5/V9@C,4$,1()BBCC)&<$H@4D9YQQQGGUYJ:BIJ,>1IOFE=\S;<
M>6%FURQ47S<_NKFM;?OS8R&"AAZ"PTH3J.K5<Y*K*I4E2]AA?9RJQ=&E&A)U
MGB%["+J\CA?VC4DYRT445B>:%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Oct. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001875091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">NeuroSense Therapeutics Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">F-3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">F-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Oct. 28, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Ordinary shares, no par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">333,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">1.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 383,334.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 52.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant to Rule 416(a) under the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the securities being registered hereunder also include such indeterminable number of additional securities as may from time to time be issued after the date hereof as a result of share splits, share dividends, recapitalizations or similar transactions.<br/><br/>Represents 333,334 ordinary shares, no par value per share (the &#8220;Ordinary Shares&#8221;), of NeuroSense Therapeutics Ltd. (the &#8220;Company&#8221;), issued in a private placement to the selling shareholder identified in the registration of which this exhibit forms a part. The Company will not receive any proceeds from the sale of its Ordinary Shares by the selling shareholder.<br/><br/>Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated under the Securities Act, as amended, based on the average of the equivalent high ($1.18) and low ($1.12) sales prices of the Ordinary Shares on the Nasdaq Capital Market on October 27, 2025.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Oct. 28, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 383,334.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">52.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 52.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea026263001ex-fee_neurosense.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea026263001ex-fee_neurosense.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea026263001ex-fee_neurosense.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="ea026263001ex-fee_neurosense.htm">ea026263001ex-fee_neurosense.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea026263001ex-fee_neurosense.htm": {
   "dts": {
    "inline": {
     "local": [
      "ea026263001ex-fee_neurosense.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/ffd/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 1
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 20,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea026263001ex-fee_neurosense.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea026263001ex-fee_neurosense.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea026263001ex-fee_neurosense.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea026263001ex-fee_neurosense.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea026263001ex-fee_neurosense.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea026263001ex-fee_neurosense.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001213900-25-103109-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-103109-xbrl.zip
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MH62V0!>2Y#<1VUHM=L?GX"Z1V.<<CU$)YA _A.SG" 68J Y&-+I@/5=K;B\
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H9F5E7VYE=7)O<V5N<V4N:'1M4$L%!@     !  $ 3@   (L+      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>ea026263001ex-fee_neurosense_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c_offering_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-28</startDate>
            <endDate>2025-10-28</endDate>
        </period>
    </context>
    <context id="c_report">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2025-10-28</startDate>
            <endDate>2025-10-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <ffd:SubmissnTp contextRef="c_report" id="fee_001">F-3</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="c_report" id="fee_002">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="c_report" id="fee_003">0001875091</dei:EntityCentralIndexKey>
    <ffd:OfferingTableNa contextRef="c_report" id="fee_004" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="c_report" id="fee_005">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="c_report" id="fee_006">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="c_report" id="fee_007">F-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c_report" id="fee_008">NeuroSense Therapeutics Ltd.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c_offering_1" id="fee_009">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_1" id="fee_010">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_1" id="fee_011">Ordinary shares, no par value per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_1" id="fee_012">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c_offering_1"
      decimals="0"
      id="fee_013"
      unitRef="shares">333334</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_014"
      unitRef="USD">1.15</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_015"
      unitRef="USD">383334.10</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_016"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_017"
      unitRef="USD">52.94</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_018"
      unitRef="USD">383334.10</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_019"
      unitRef="USD">52.94</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_020"
      unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_021"
      unitRef="USD">52.94</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c_offering_1" id="fee_022">Pursuant to Rule 416(a) under the U.S. Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the securities being registered hereunder also include such indeterminable number of additional securities as may from time to time be issued after the date hereof as a result of share splits, share dividends, recapitalizations or similar transactions.&lt;br/&gt;&lt;br/&gt;Represents 333,334 ordinary shares, no par value per share (the &#x201c;Ordinary Shares&#x201d;), of NeuroSense Therapeutics Ltd. (the &#x201c;Company&#x201d;), issued in a private placement to the selling shareholder identified in the registration of which this exhibit forms a part. The Company will not receive any proceeds from the sale of its Ordinary Shares by the selling shareholder.&lt;br/&gt;&lt;br/&gt;Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated under the Securities Act, as amended, based on the average of the equivalent high ($1.18) and low ($1.12) sales prices of the Ordinary Shares on the Nasdaq Capital Market on October 27, 2025.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
